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This application is a National Phase filing of PCT/US2011/ 
055962, filed Oct. 12, 2011, which claims priority from U.S. 
Provisional Application No. 61/392.237, filed Oct. 12, 2010, 
the subject matter of which are incorporated herein by refer 
ence in their entirety. 
TECHNICAL FIELD 
This application relates to purine-based triazoles and to the 
use of the purine-based triazoles as protein kinase inhibitors 
and to treat diseases or disorders associated with protein 
kinases. 
BACKGROUND OF THE INVENTION 
Initiation, progression, and completion of the mammalian 
cell cycle are regulated by various cyclin-dependent kinase 
(CDK) complexes, which are critical for cell growth. CDKs 
are highly conserved among eukaryotic species. Higher 
eukaryotic cells contain several isoforms of CDKs that 
become activated in specific phases of the cell cycle. CDKs 
consist of a catalytic subunit, the prototype of which is CDC2, 
and a regulatory subunit (cyclin). Six human CDK proteins 
have been described so far (see, Meyerson, M., et al. (1992), 
EMBO J., 11:2909-2917; Meyerson, M., et al. (1994), Mol. 
Cell. Biol., 14:2077-2086; and Van den Heuvel, S., et al. 
(1993), Science, 262:2050-2054), namely, CDK1 (also 
known as CDC2) and CDK2-6. With the exception of CDK3, 
for which the regulatory cyclin has not yet been identified, all 
these CDK proteins are regulated by the transient association 
with one member of the cyclin family, i.e., cyclin A (CDC2, 
CDK2), B1-B3 (CDC2), D1-D3 (CDK2, CDK4, CDK5, 
CDK6), E (CDK2). Each step of the cell cycle is thought to be 
regulated by such CDK complexes: G1/S transition (CDK2/ 
cyclin E, CDK3/unknown cyclin, CDK4/cyclin D1-D3, 
CDK6/cyclin D3), S phase (CDK2/cyclin A), G2 (CDC2/ 
cyclin A), G2/M transition (CDC2/cyclins B). 
The function of CDKs is to phosphorylate and thus activate 
or deactivate certain proteins, including e.g., retinoblastoma 
proteins, lamins, histone H1, and components of the mitotic 
spindle. The catalytic step mediated by CDKs involves a 
phospho-transfer reaction from ATP to the macromolecular 
enzyme Substrate. Several groups of compounds (reviewed in 
e.g., Fischer, P. M. Curr. Opin. Drug Discovery Dev. 2001, 4, 
623-634) have been found to possess anti-proliferative prop 
erties by virtue of CDK-specific ATP antagonism. 
WO 98/05335 discloses 2.6.9-trisubstituted purine deriva 
tives that are selective inhibitors of cell cycle kinases. Such 
compounds are useful in the treatment of autoimmune disor 
ders, e.g., rheumatoid arthritis, lupus, type I diabetes, mul 
tiple Sclerosis; treating cancer, cardiovascular disease. Such 
as restenosis, host V graft disease, gout, polycystic kidney 
disease and other proliferative diseases whose pathogenesis 
involves abnormal cell proliferation. 
WO99/07705 discloses purine analogues that inhibit inter 
alia protein kinases, G-proteins and polymerases. More spe 
cifically, WO 705 discloses methods of using such purine 
analogues to treat cellular proliferative disorders and neuro 
degenerative diseases. 
WO97/20842 also discloses purine derivatives displaying 
antiproliferative properties, which are useful in treating can 













SUMMARY OF THE INVENTION 
This application relates to substituted purine-based triaz 
oles that can inhibit protein kinases, such as cyclin-dependent 
kinase (CDK), G proteins and polymerases, as well as phar 
maceutical compositions comprising the same, and methods 
for formulating or using the same to treat diseases or disorders 
associated with protein kinases, G proteins and plymerases. 
In one embodiment, the Substituted purine-based analog 
can include the following formula (I): 
(I) 
R y- / -Q 
N SN R 
or a pharmaceutically acceptable salt thereof, wherein 
where R is a hydrophobic, substituted or unsubstituted, 
aryl, cyclic, or heterocyclic group; 
where R and R independently represent Substituents 
Selected from the group consisting of hydrogen, halogen 
atom, C1-C4 alkyl, C-C2 alkenyl, C2-C2a alkynyl, 
Cs-Co aryl, C-C alkaryl, C-C aralkyl, silyl, 
hydroxyl, Sulfhydryl, C-C alkoxy, C-C alkeny 
loxy, C-C alkynyloxy, Cs-Co aryloxy, acyl, C-C 
alkylcarbonyl (—CO-alkyl). Co-Co arylcarbonyl 
(—CO-aryl)), acyloxy ( O-acyl), C-C alkoxycarbo 
nyl (-(CO)—O-alkyl). Co-Co aryloxycarbonyl 
(—(CO)—O-aryl), C-C alkylcarbonato (-O- 
(CO)—O-alkyl), C-C arylcarbonato ( O—(CO)— 
O-aryl), carboxy ( -COOH), carboxylato (-COO), 
carbamoyl (-(CO)—NH), mono-(C-C alkyl)-Sub 
stituted carbamoyl (—(CO)—NH(C-C alkyl)), di 
(C-C alkyl)-substituted carbamoyl (—(CO)—N(C- 
C alkyl)), mono-substituted arylcarbamoyl 
(—(CO). NH-aryl), thiocarbamoyl (—(CS) NH), 
carbamido ( NH-(CO) NH), cyano ( CN), iso 
cyano ( NC), cyanato ( O—CN), isocyanato (ONC), 
isothiocyanato (—S CN), azido ( N=N*—N), 
formyl (—(CO)—H), thioformyl ( (CS)—H), amino 
(—NH), mono- and di-(C-C alkyl)-substituted 
amino, mono- and di-(C-C aryl)-substituted amino, 
C-C alkylamido (—NH-(CO)-alkyl). Co-Co aryla 
mido ( NH (CO)-aryl), imino, alkylimino, 
arylimino, nitro ( NO), nitroso ( NO), sulfonic acid 
(—SO-OH), sulfonato ( SO O), C-C alkylsul 
fanyl ( S-alkyl), arylsulfanyl, C-C alkylsulfinyl 
(—(SO)-alkyl), Cs-Co arylsulfinyl (—(SO)-aryl), 
C-C alkylsulfonyl (—SO-alkyl), Cs-Co arylsulfo 
nyl ( SO-aryl), phosphono ( P(O)(OH)), phospho 
nato ( P(O)(O ),), phosphinato ( P(O)(O)), phos 
pho ( PO), and phosphino ( -PH), and where each 
R and R being independently unsubstituted or Substi 
tuted where appropriate by one or more —OH, halogen, 
amino or alkyl groups. 
In some embodiments, R is a fluorinated aryl, cyclic, or 
heterocyclic group. In other embodiments R and R are each 
independently a halogen atom, C-C alkyl, C-C alkenyl, 
C2-C2-alkynyl, Ca-Cao aryl, C-C2-alkaryl, C-C2a aralkyl, 
or an R. NH-, R. NH-NH , NH R NH or 
R. NH R' NH radical, in which Ra represents a 
straight- or branched-chain, Saturated or unsaturated alkyl 
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radical, an aryl or cycloalkyl radical or a heterocyclic ring and 
R" represents a straight- or branched-chain, Saturated or 
unsaturated alkylene group or an arylene or cycloalkylene 
group, where R and Reach contain 1 to 8 carbonatoms, and 
where each R and R can be independently unsubstituted or 
substituted, where appropriate, by one or more —OH, halo 
gen, amino or alkyl groups. 
Another embodiment of the application relates to a method 
of inhibiting a protein selected from the group consisting of 
protein kinases, G proteins and polymerases by contacting the 
protein with a substituted purine-based triazole. In some 
embodiments, the protein is a protein kinase. In other 
embodiments, the protein kinase is a cyclin-dependent 
kinase. In still other embodiments, the cyclin-dependent 
kinase is a member selected from the group consisting of 
CDK1 (CDC2), CDK2, CDK3, CDK4, CDK5, CDK6, 
CDK7 and CDK8 and, in particular CDK5. 
Yet another embodiment of the application relates to the 
use of the Substituted purine-based triazole in treating a dis 
ease process featuring abnormal cell cycle or cellular prolif 
eration, including, but not limited to, abnormal stimulation of 
endothelial cells (e.g., atherosclerosis), neoplastic disorders, 
Solid tumors and tumor metastasis, benign tumors, for 
example, hemangiomas, acoustic neuromas, neurofibromas, 
trachomas, and pyogenic granulomas, cancer, Vascular mal 
functions, abnormal wound healing, inflammatory and 
immune disorders, Bechet's disease, gout or gouty arthritis, 
abnormal angiogenesis accompanying, for example, rheuma 
toid arthritis, psoriasis, diabetic retinopathy, other ocular 
angiogenic diseases, such as retinopathy of prematurity (ret 
rolental fibroplastic), macular degeneration, corneal graft 
rejection, neuroscular glaucoma and Oster Webber syn 
drome, alopecia, fungal, parasitic and viral infections, such as 
cytomegaloviral infections, neurological disorders, stroke 
neurofibromatosis, endotoxic shock, hypertrophic scar for 
mation, inflammatory bowel disease, transplant rejection, 
vascular Smooth muscle cell proliferation associated with 
atherosclerosis, pulmonary fibrosis, arthritis, glomerulone 
phritis, restenosis following angioplasty or vascular Surgery, 
and other post-Surgical Stenosis and restenosis. 
In some embodiments, the disease or disorder treated by 
the Substituted purine-based triazole is a neurological disor 
der. In other embodiments, the disease or disorder treated by 
the substituted purine-based triazole is a neoplastic disorder. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The foregoing and other features of the application will 
become apparent to those skilled in the art to which the 
application relates upon reading the following description 
with reference to the accompanying drawings, in which: 
FIG. 1 illustrates fluorescence microscopy images showing 
the time-dependent PI uptake in hippocampal slices exposed 
to 5 uMoligomers. 
FIG. 2 illustrates a chart showing PI uptake responses 
between groups. 
FIG.3 illustrates fluorescence microscopy images showing 
the relative PI uptake in hippocampal slices incubated with 
various compounds (1 uM; 1 h) followed by AB oligomers (5 
uM; 48 h). 
FIG. 4 illustrates a chart showing PIuptake responses. Data 
were expressed as the means-S.E. (n=4). Differences 
between groups were examined for statistical significance 
using one-way analysis of variance with an unpaired Students 
t-test (*: p<0.05; #: p<0.05, #: p<0.01). 
FIG.5 illustrates a schematic view of potential Roscovitine 













GenDock simulations; Region A is the highest scoring site in 
accordance with co-crystal structure. 1UNL. 
FIG. 6 illustrates an expanded view of the Roscovitine 
CDK5/p25 complex showing the X-ray structure (1UNL) 
superimposed on the DarwinDock/GenDock simulated struc 
ture. 
FIG. 7 illustrates an expanded view of the Compound 
7-CDK5/p25 complex, showing hydrogen bonds to Lys89, 
Ile10, Asn144 and Gln130. 
DETAILED DESCRIPTION 
For convenience, certain terms employed in the specifica 
tion, examples, and appended claims are collected here. 
Unless defined otherwise, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which this application 
belongs. 
The articles “a” and “an are used herein to refer to one or 
to more than one (i.e., to at least one) of the grammatical 
object of the article. By way of example, “an element’ means 
one element or more than one element. 
The terms “comprise.” “comprising.” “include.” “includ 
ing,” “have.” and “having are used in the inclusive, open 
sense, meaning that additional elements may be included. 
The terms "such as”, “e.g., as used herein are non-limiting 
and are for illustrative purposes only. “Including and 
“including but not limited to are used interchangeably. 
The term 'or' as used herein should be understood to mean 
“and/or, unless the context clearly indicates otherwise. 
It will be noted that the structure of some of the compounds 
of the application include asymmetric (chiral) carbon atoms. 
It is to be understood accordingly that the isomers arising 
from such asymmetry are included within the scope of the 
invention, unless indicated otherwise. Such isomers can be 
obtained in Substantially pure form by classical separation 
techniques and by Stereochemically controlled synthesis. The 
compounds of this application may exist in Stereoisomeric 
form, therefore can be produced as individual stereoisomers 
or as mixtures. 
“Isomerism” means compounds that have identical 
molecular formulae but that differ in the nature or the 
sequence of bonding of their atoms or in the arrangement of 
their atoms in space. Isomers that differ in the arrangement of 
their atoms in space are termed “stereoisomers'. Stereoiso 
mers that are not mirror images of one another are termed 
"diastereoisomers', and stereoisomers that are non-Superim 
posable mirror images are termed “enantiomers', or some 
times optical isomers. A carbonatom bonded to four noniden 
tical substituents is termed a "chiral center'. 
“Chiral isomer means a compound with at least one chiral 
center. It has two enantiomeric forms of opposite chirality and 
may exist either as an individual enantiomer or as a mixture of 
enantiomers. A mixture containing equal amounts of indi 
vidual enantiomeric forms of opposite chirality is termed a 
“racemic mixture'. A compound that has more than one chiral 
center has 2n-1 enantiomeric pairs, where n is the number of 
chiral centers. Compounds with more than one chiral center 
may exist as either an individual diastereomer or as a mixture 
of diastereomers, termed a "diastereomeric mixture'. When 
one chiral center is present, a stereoisomer may be character 
ized by the absolute configuration (R or S) of that chiral 
center. Absolute configuration refers to the arrangement in 
space of the substituents attached to the chiral center. The 
substituents attached to the chiral center under consideration 
are ranked in accordance with the Sequence Rule of Cahn, 
Ingold and Prelog. (Cahn et al. Angew. Chem. Inter. Edit. 
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1966, 5,385; errata 511; Cahn et al., Angew. Chem. 1966,78, 
413: Cahn and Ingold, J Chem. Soc. 1951 (London), 612: 
Cahn et al., Experientia 1956, 12, 81; Cahn, J., Chem. Educ. 
1964, 41, 116). 
“Geometric Isomers' means the diastereomers that owe 
their existence to hindered rotation about double bonds. 
These configurations are differentiated in their names by the 
prefixes cis and trans, or Z and E, which indicate that the 
groups are on the same or opposite side of the double bond in 
the molecule according to the Cahn-Ingold-Prelog rules. 
Further, the structures and other compounds discussed in 
this application include all atropic isomers thereof. 'Atropic 
isomers' area type of stereoisomer in which the atoms of two 
isomers are arranged differently in space. Atropic isomers 
owe their existence to a restricted rotation caused by hin 
drance of rotation of large groups about a central bond. Such 
atropic isomers typically exist as a mixture, however as a 
result of recent advances in chromatography techniques, it 
has been possible to separate mixtures of two atropic isomers 
in select cases. 
The terms “crystal polymorphs' or “polymorphs' or “crys 
tal forms' means crystal structures in which a compound (or 
salt or solvate thereof) can crystallize in different crystal 
packing arrangements, all of which have the same elemental 
composition. Different crystal forms usually have different 
X-ray diffraction patterns, infrared spectra, melting points, 
density hardness, crystal shape, optical and electrical proper 
ties, stability and solubility. Recrystallization solvent, rate of 
crystallization, storage temperature, and other factors may 
cause one crystal form to dominate. Crystal polymorphs of 
the compounds can be prepared by crystallization under dif 
ferent conditions. 
As defined herein, the term "derivative', refers to com 
pounds that have a common core structure, and are substituted 
with various groups as described herein. For example, all of 
the compounds represented by formula I are purine-based 
triazoles and have formula I as a common core. 
The term “bioisostere” refers to a compound resulting from 
the exchange of an atom or of a group of atoms with another, 
broadly similar, atom or group of atoms. The objective of a 
bioisosteric replacement is to create a new compound with 
similar biological properties to the parent compound. The 
bioisosteric replacement may be physicochemically or topo 
logically based. Examples of carboxylic acid bioisosteres 
include acyl Sulfonimides, tetrazoles, Sulfonates, and phos 
phonates. See, e.g., Patani and LaVoie, Chem. Rev. 96, 3147 
3176 (1996). 
The phrases “parenteral administration' and “adminis 
tered parenterally are art-recognized terms, and include 
modes of administration other than enteral and topical admin 
istration, Such as injections, and include, without limitation, 
intravenous, intramuscular, intrapleural, intravascular, intra 
pericardial, intraarterial, intrathecal, intracapsular, intraor 
bital, intracardiac, intradermal, intraperitoneal, transtracheal, 
Subcutaneous, Subcuticular, intra-articular, Subcapsular, Sub 
arachnoid, intraspinal and intrastemal injection and infusion. 
The term “treating is art-recognized and includes inhibit 
ing a disease, disorder or condition in a subject, e.g., imped 
ing its progress; and relieving the disease, disorder or condi 
tion, e.g., causing regression of the disease, disorder and/or 
condition. Treating the disease or condition includes amelio 
rating at least one symptom of the particular disease or con 
dition, even if the underlying pathophysiology is not affected. 
The term “preventing is art-recognized and includes stop 
ping a disease, disorder or condition from occurring in a 
Subject, which may be predisposed to the disease, disorder 














Preventing a condition related to a disease includes stopping 
the condition from occurring after the disease has been diag 
nosed but before the condition has been diagnosed. 
A "pharmaceutical composition' is a formulation contain 
ing the disclosed compounds in a form Suitable for adminis 
tration to a Subject. In a preferred embodiment, the pharma 
ceutical composition is in bulk or in unit dosage form. The 
unit dosage form is any of a variety of forms, including, for 
example, a capsule, an IV bag, a tablet, a single pump on an 
aerosol inhaler, or a vial. The quantity of active ingredient 
(e.g., a formulation of the disclosed compound or salts 
thereof) in a unit dose of composition is an effective amount 
and is varied according to the particular treatment involved. 
One skilled in the art will appreciate that it is sometimes 
necessary to make routine variations to the dosage depending 
on the age and condition of the patient. The dosage will also 
depend on the route of administration. A variety of routes are 
contemplated, including oral, pulmonary, rectal, parenteral, 
transdermal. Subcutaneous, intravenous, intramuscular, intra 
peritoneal, intranasal, and the like. Dosage forms for the 
topical or transdermal administration of a compound of this 
invention include powders, sprays, ointments, pastes, creams, 
lotions, gels, Solutions, patches and inhalants. In a preferred 
embodiment, the active compound is mixed under sterile 
conditions with a pharmaceutically acceptable carrier, and 
with any preservatives, buffers, or propellants that are 
required. 
The term “flash dose' refers to compound formulations 
that are rapidly dispersing dosage forms. 
The term “immediate release' is defined as a release of 
compound from a dosage form in a relatively brief period of 
time, generally up to about 60 minutes. The term “modified 
release' is defined to include delayed release, extended 
release, and pulsed release. The term “pulsed release' is 
defined as a series of releases of drug from a dosage form. The 
term “sustained release' or “extended release' is defined as 
continuous release of a compound from a dosage form over a 
prolonged period. 
The phrase “pharmaceutically acceptable' is art-recog 
nized. In certain embodiments, the term includes composi 
tions, polymers and other materials and/or dosage forms 
which are, within the scope of sound medical judgment, Suit 
able for use in contact with the tissues of human beings and 
animals without excessive toxicity, irritation, allergic 
response, or other problem or complication, commensurate 
with a reasonable benefit/risk ratio. 
The phrase “pharmaceutically acceptable carrier' is art 
recognized, and includes, for example, pharmaceutically 
acceptable materials, compositions or vehicles, such as a 
liquid or Solid filler, diluent, excipient, solvent or encapsulat 
ing material, involved in carrying or transporting any subject 
composition from one organ, or portion of the body, to 
another organ, or portion of the body. Each carrier must be 
“acceptable in the sense of being compatible with the other 
ingredients of a Subject composition and not injurious to the 
patient. In certain embodiments, a pharmaceutically accept 
able carrier is non-pyrogenic. Some examples of materials 
which may serve as pharmaceutically acceptable carriers 
include: (1) Sugars, such as lactose, glucose and Sucrose; (2) 
starches, such as corn starch and potato starch; (3) cellulose, 
and its derivatives, such as Sodium carboxymethyl cellulose, 
ethyl cellulose and cellulose acetate; (4) powdered traga 
canth; (5) malt, (6) gelatin; (7) talc.; (8) excipients, such as 
cocoa butter and Suppository waxes; (9) oils, such as peanut 
oil, cottonseed oil, Sunflower oil, sesame oil, olive oil, corn oil 
and Soybean oil, (10) glycols, such as propylene glycol; (11) 
polyols. Such as glycerin, Sorbitol, mannitol and polyethylene 
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glycol, (12) esters, such as ethyl oleate and ethyl laurate; (13) 
agar, (14) buffering agents, such as magnesium hydroxide 
and aluminum hydroxide; (15) alginic acid, (16) pyrogen 
free water; (17) isotonic saline; (18) Ringer's solution; (19) 
ethyl alcohol; (20) phosphate buffer solutions; and (21) other 
non-toxic compatible Substances employed in pharmaceuti 
cal formulations. 
The compounds of the application are capable of further 
forming salts. All of these forms are also contemplated within 
the scope of the claimed invention. 
"Pharmaceutically acceptable salt” of a compound means a 
salt that is pharmaceutically acceptable and that possesses the 
desired pharmacological activity of the parent compound. 
For example, the salt can be an acid addition salt. One 
embodiment of an acid addition salt is a hydrochloride salt 
The pharmaceutically acceptable salts can be synthesized 
from a parent compound that contains a basic oracidic moiety 
by conventional chemical methods. Generally, such salts can 
be prepared by reacting the free acid or base forms of these 
compounds with a stoichiometric amount of the appropriate 
base or acid in water or in an organic solvent, or in a mixture 
of the two: generally, non-aqueous media like ether, ethyl 
acetate, ethanol, isopropanol, or acetonitrile are preferred. 
Lists of salts are found in Remington's Pharmaceutical Sci 
ences, 18th ed. (Mack Publishing Company, 1990). For 
example, salts can include, but are not limited to, the hydro 
chloride and acetate salts of the aliphatic amine-containing, 
hydroxyl amine-containing, and imine-containing com 
pounds of the present invention. 
It should be understood that all references to pharmaceu 
tically acceptable salts include solvent addition forms (sol 
vates) or crystal forms (polymorphs) as defined herein, of the 
same salt. 
The compounds described herein can also be prepared as 
esters, for example pharmaceutically acceptable esters. For 
example, a carboxylic acid function group in a compound can 
be converted to its corresponding ester, e.g., a methyl, ethyl, 
or other ester. Also, an alcohol group in a compound can be 
converted to its corresponding ester, e.g., an acetate, propi 
onate, or other ester. 
The compounds described herein can also be prepared as 
prodrugs, for example pharmaceutically acceptable prodrugs. 
The terms “pro-drug and “prodrug are used interchange 
ably herein and refer to any compound, which releases an 
active parent drug in vivo. Since prodrugs are known to 
enhance numerous desirable qualities of pharmaceuticals 
(e.g., solubility, bioavailability, manufacturing, etc.) the com 
pounds of the present invention can be delivered in prodrug 
form. Thus, the present invention is intended to cover pro 
drugs of the presently claimed compounds, methods of deliv 
ering the same and compositions containing the same. "Pro 
drugs are intended to include any covalently bonded carriers 
that release an active parent drug of the present invention in 
Vivo when such prodrug is administered to a subject. Prodrugs 
of the present invention are prepared by modifying functional 
groups present in the compound in Such a way that the modi 
fications are cleaved, eitherin routine manipulation or in Vivo, 
to the parent compound. Prodrugs include compounds of the 
present invention wherein a hydroxy, amino, Sulfhydryl, car 
boxy, or carbonyl group is bonded to any group that may be 
cleaved in vivo to form a free hydroxyl, free amino, free 
sulftydryl, free carboxy or free carbonyl group, respectively. 
Examples of prodrugs include, but are not limited to, esters 
(e.g., acetate, dialkylaminoacetates, formates, phosphates, 
Sulfates, and benzoate derivatives) and carbamates (e.g., N.N- 
dimethylaminocarbonyl) of hydroxy functional groups, ester 













boxyl functional groups, N-acyl derivatives (e.g., N-acetyl) 
N-Mannich bases, Schiffbases and enamines of amino func 
tional groups, oximes, acetals, ketals and enolesters of ketone 
and aldehyde functional groups in compounds of Formula I, 
and the like, See Bundegaard, H. “Design of Prodrugs' p1-92, 
Elesevier, New York-Oxford (1985). 
“Protecting group' refers to a grouping of atoms that when 
attached to a reactive group in a molecule masks, reduces or 
prevents that reactivity. Examples of protecting groups can be 
found in Green and Wuts, Protective Groups in Organic 
Chemistry, (Wiley, 2. Sup.nded. 1991); Harrison and Harrison 
et al., Compendium of Synthetic Organic Methods, Vols. 1-8 
(John Wiley and Sons, 1971-1996); and Kocienski, Protect 
ing Groups, (Verlag, 3.sup.rd ed. 2003). 
Representative hydroxy protecting groups include those 
where the hydroxy group is either acylated or alkylated Such 
as benzyl, and trityl ethers as well as alkyl ethers, tetrahydro 
pyranyl ethers, trialkylsilyl ethers and allyl ethers. 
Additionally, the salts of the compounds described herein, 
can exist in either hydrated or unhydrated (the anhydrous) 
form or as solvates with other solvent molecules. Nonlimiting 
examples of hydrates include monohydrates, dihydrates, etc. 
Nonlimiting examples of Solvates include ethanol Solvates, 
acetone Solvates, etc. 
“Solvates' means solvent addition forms that contain 
either Stoichiometric or non Stoichiometric amounts of Sol 
vent. Some compounds have a tendency to trap a fixed molar 
ratio of solvent molecules in the crystalline solid state, thus 
forming a solvate. If the solvent is water the solvate formed is 
a hydrate, when the solvent is alcohol, the solvate formed is an 
alcoholate. Hydrates are formed by the combination of one or 
more molecules of water with one of the substances in which 
the water retains its molecular state as HO, such combination 
being able to form one or more hydrate. 
The compounds, salts and prodrugs described herein can 
exist in several tautomeric forms, including the enol and 
imine form, and the keto and enamine form and geometric 
isomers and mixtures thereof. All Such tautomeric forms are 
included within the scope of the present invention. Tautomers 
exist as mixtures of a tautomeric set in Solution. In solid form, 
usually one tautomer predominates. Even though one tau 
tomer may be described, the present application includes all 
tautomers of the present compounds. A tautomer is one of two 
or more structural isomers that exist in equilibrium and are 
readily converted from one isomeric form to another. This 
reaction results in the formal migration of a hydrogen atom 
accompanied by a Switch of adjacent conjugated double 
bonds. In solutions where tautomerization is possible, a 
chemical equilibrium of the tautomers will be reached. The 
exact ratio of the tautomers depends on several factors, 
including temperature, solvent, and pH. The concept of tau 
tomers that are interconvertable by tautomerizations is called 
tautomerism. 
Of the various types of tautomerism that are possible, two 
are commonly observed. In keto-enol tautomerism a simul 
taneous shift of electrons and a hydrogen atom occurs. 
Tautomerizations can be catalyzed by: Base: 1. deprotona 
tion; 2. formation of a delocalized anion (e.g., an enolate); 3. 
protonation at a different position of the anion, Acid: 1. pro 
tonation; 2. formation of a delocalized cation; 3. deprotona 
tion at a different position adjacent to the cation. 
As used herein, the term “analog refers to a chemical 
compound that is structurally similar to another but differs 
slightly in composition (as in the replacement of one atom by 
an atom of a different element or in the presence of a particu 
lar functional group, or the replacement of one functional 
group by another functional group). Thus, an analog is a 
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compound that is similar or comparable in function and 
appearance, but not in structure or origin to the reference 
compound. 
A“patient,” “subject” or “host to be treated by the subject 
method may mean either a human or non-human animal. Such 
as primates, mammals, and vertebrates. 
The term “prophylactic or therapeutic' treatment is art 
recognized and includes administration to the host of one or 
more of the Subject compositions. If it is administered prior to 
clinical manifestation of the unwanted condition (e.g., dis 
ease or other unwanted state of the host animal) then the 
treatment is prophylactic, i.e., it protects the host against 
developing the unwanted condition, whereas if it is adminis 
tered after manifestation of the unwanted condition, the treat 
ment is therapeutic (i.e., it is intended to diminish, ameliorate, 
or stabilize the existing unwanted condition or side effects 
thereof). 
The terms “therapeutic agent”, “drug”, “medicament” and 
“bioactive Substance' are art-recognized and include mol 
ecules and other agents that are biologically, physiologically, 
or pharmacologically active Substances that act locally or 
systemically in a patient or subject to treat a disease or con 
dition. The terms include without limitation pharmaceuti 
cally acceptable salts thereof and prodrugs. Such agents may 
be acidic, basic, or salts; they may be neutral molecules, polar 
molecules, or molecular complexes capable of hydrogen 
bonding; they may be prodrugs in the form of ethers, esters, 
amides and the like that are biologically activated when 
administered into a patient or Subject. 
The phrase “therapeutically effective amount' is an art 
recognized term. In certain embodiments, the term refers to 
an amount of a therapeutic agent that, when incorporated into 
a polymer, produces some desired effect at a reasonable ben 
efit/risk ratio applicable to any medical treatment. In certain 
embodiments, the term refers to that amount necessary or 
Sufficient to eliminate, reduce or maintain a target of a par 
ticular therapeutic regimen. The effective amount may vary 
depending on Such factors as the disease or condition being 
treated, the particular targeted constructs being administered, 
the size of the subject or the severity of the disease or condi 
tion. One of ordinary skill in the art may empirically deter 
mine the effective amount of a particular compound without 
necessitating undue experimentation. In certain embodi 
ments, a therapeutically effective amount of a therapeutic 
agent for in vivo use will likely depend on a number of factors, 
including: the rate of release of an agent from a polymer 
matrix, which will depend in part on the chemical and physi 
cal characteristics of the polymer; the identity of the agent; 
the mode and method of administration; and any other mate 
rials incorporated in the polymer matrix in addition to the 
agent. 
The term "ED50 is art-recognized. In certain embodi 
ments, ED50 means the dose of a drug, which produces 50% 
of its maximum response or effect, or alternatively, the dose, 
which produces a pre-determined response in 50% of test 
subjects or preparations. The term “LD50 is art-recognized. 
In certain embodiments, LD50 means the dose of a drug, 
which is lethal in 50% of test subjects. The term “therapeutic 
index' is an art-recognized term, which refers to the thera 
peutic index of a drug, defined as LD50/ED50. 
The term “substituted as used herein, means that any one 
or more hydrogens on the designated atom is replaced with a 
selection from the indicated group, provided that the desig 
nated atoms normal valency is not exceeded, and that the 
substitution results in a stable compound. When the substitu 














replaced. Ring double bonds, as used herein, are double 
bonds that are formed between two adjacent ring atoms (e.g., 
C-C, C—N, O N—N). 
With respect to any chemical compounds, the present 
application is intended to include all isotopes of atoms occur 
ring in the present compounds. Isotopes include those atoms 
having the same atomic number but different mass numbers. 
By way of general example and without limitation, isotopes 
of hydrogen include tritium and deuterium, and isotopes of 
carbon include C-13 and C-14. 
When a bond to a substituent is shown to cross a bond 
connecting two atoms in a ring, then Such substituent can be 
bonded to any atom in the ring. When a substituent is listed 
without indicating the atom via which Such Substituent is 
bonded to the rest of the compound of a given formula, then 
Such substituent can be bonded via any atom in Such substitu 
ent. Combinations of substituents and/or variables are per 
missible, but only if such combinations result in stable com 
pounds. 
When an atom or a chemical moiety is preceded or fol 
lowed by a subscripted numeric range (e.g., C.), the inven 
tion is meant to encompass each number within the range as 
well as all intermediate ranges. For example, “C. alkyl or 
is meant to include alkyl groups with 1, 2, 3, 4, 5, 6, 1-6, 1-5, 
1-4, 1-3, 1-2, 2-6, 2-5, 2-4, 2-3, 3-6, 3-5, 3-4, 4-6, 4-5, and 5-6 
carbons. 
As used herein, “alkyl is intended to include both 
branched (e.g., isopropyl, tert-butyl, isobutyl), straight-chain 
e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, 
nonyl, decyl), and cycloalkyl (e.g., alicyclic) groups (e.g., 
cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooc 
tyl), alkyl substituted cycloalkyl groups, and cycloalkyl sub 
stituted alkyl groups. Such aliphatic hydrocarbon groups 
have a specified number of carbon atoms. For example, C. 
alkyl is intended to include C, C, C, C, Cs, and C alkyl 
groups. As used herein, “lower alkyl refers to alkyl groups 
having from 1 to 6 carbonatoms in the backbone of the carbon 
chain. “Alkyl further includes alkyl groups that have oxygen, 
nitrogen, Sulfur orphosphorous atoms replacing one or more 
hydrocarbon backbone carbon atoms. In certain embodi 
ments, a straight chain or branched chain alkyl has six or 
fewer carbon atoms in its backbone (e.g., C-C for straight 
chain, C-C for branched chain), for example four or fewer. 
Likewise, certain cycloalkyls have from three to eight carbon 
atoms in their ring structure. Such as five or six carbons in the 
ring structure. 
The term “substituted alkyls' refers to alkyl moieties hav 
ing Substituents replacing a hydrogen on one or more carbons 
of the hydrocarbon backbone. Such substituents can include, 
for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alky 
lcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxy 
carbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, 
alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, 
dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phos 
phate, phosphonato, phosphinato, cyano, amino (including 
alkylamino, dialkylamino, arylamino, diarylamino, and alky 
larylamino), acylamino (including alkylcarbonylamino, aryl 
carbonylamino, carbamoylandureido), amidino, imino, Sulf 
hydryl, alkylthio, arylthio, thiocarboxylate, sulfates, 
alkylsulfinyl, Sulfonato, Sulfamoyl, Sulfonamido, nitro, trif 
luoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aro 
matic or heteroaromatic moiety. Cycloalkyls can be further 
substituted, e.g., with the substituents described above. An 
“alkylaryl' or an “aralkyl moiety is an alkyl substituted with 
an aryl (e.g., phenylmethyl (benzyl)). 
As used herein, “alkenyl is intended to include hydrocar 
bon chains of either straight or branched configuration having 
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one or more carbon-carbon double bonds occurring at any 
stable point along the chain. For example, C. alkenyl is 
intended to include C, C, C, Cs, and Coalkenyl groups. 
Examples of alkenyl include, but are not limited to, ethenyl 
and propenyl. 
As used herein, “alkynyl' is intended to include hydrocar 
bon chains of either straight or branched configuration having 
one or more carbon-carbon triple bonds occurring at any 
stable point along the chain. For example, C alkynyl is 
intended to include C, C, C, Cs, and C alkynyl groups. 
Examples of alkynyl include, but are not limited to, ethynyl 
and propynyl. 
Furthermore, “alkyl”, “alkenyl', and “alkynyl are 
intended to include moieties which are diradicals, i.e., having 
two points of attachment. A nonlimiting example of Such an 
alkyl moiety that is a diradical is —CH2CH2—, i.e., a Calkyl 
group that is covalently bonded via each terminal carbon 
atom to the remainder of the molecule. 
Aryl includes groups with aromaticity, including 5- and 
6-membered “unconjugated, or single-ring, aromatic groups 
that may include from Zero to four heteroatoms, as well as 
"conjugated, or multicyclic, systems with at least one aro 
matic ring. Examples of aryl groups include benzene, Substi 
tuted phenyl, pyrrole, furan, thiophene, thiazole, isothiazole, 
imidazole, triazole, tetrazole, pyrazole, oxazole, isooxazole, 
pyridine, pyrazine, pyridazine, and pyrimidine, and the like. 
Furthermore, the term “aryl' includes multicyclic aryl 
groups, e.g., tricyclic, bicyclic, e.g., naphthalene, benzoX 
azole, benzodioxazole, benzothiazole, benzoimidazole, ben 
Zothiophene, methylenedioxyphenyl, quinoline, isoquino 
line, napthridine, indole, benzofuran, purine, benzofuran, 
deazapurine, or indolizine. Those aryl groups having heteroa 
toms in the ring structure may also be referred to as “aryl 
heterocycles”, “heterocycles,” “heteroaryls' or "heteroaro 
matics’. The aromatic ring can be substituted at one or more 
ring positions with Such substituents as described above, as 
for example, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, 
arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, 
carboxylate, alkylcarbonyl, alkylaminocarbonyl, aralkylami 
nocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcar 
bonyl, aralkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, 
aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, 
phosphinato, cyano, amino (including alkylamino, dialky 
lamino, arylamino, diarylamino, and alkylaryl amino), acy 
lamino (including alkylcarbonylamino, arylcarbonylamino, 
carbamoylandureido), amidino, imino, Sulfhydryl, alkylthio. 
arylthio, thiocarboxylate, Sulfates, alkylsulfinyl, Sulfonato, 
Sulfamoyl, Sulfonamido, nitro, trifluoromethyl, cyano, azido, 
heterocyclyl, alkylaryl, or an aromatic or heteroaromatic 
moiety. Aryl groups can also be fused or bridged with alicy 
clic or heterocyclic rings, which are not aromatic So as to form 
a multicyclic system (e.g., tetralin, methylenedioxyphenyl). 
The terms "heterocyclyl or "heterocyclic group' include 
closed ring structures, e.g., 3- to 10-, or 4- to 7-membered 
rings, which include one or more heteroatoms. “Heteroatom’ 
includes atoms of any element other than carbon or hydrogen. 
Examples of heteroatoms include nitrogen, oxygen, Sulfur 
and phosphorus. 
Heterocyclyl groups can be saturated or unsaturated and 
include pyrrolidine, oxolane, thiolane, piperidine, piperazine, 
morpholine, lactones, lactams such as azetidinones and pyr 
rolidinones, Sultams, and Sultones. Heterocyclic groups such 
as pyrrole and furan can have aromatic character. They 
include fused ring structures such as quinoline and isoquino 
line. Other examples of heterocyclic groups include pyridine 
and purine. The heterocyclic ring can be substituted at one or 













for example, halogen, hydroxyl, alkylcarbonyloxy, arylcar 
bonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, car 
boxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, 
alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phos 
phinato, cyano, amino (including alkylamino, dialkylamino, 
arylamino, diarylamino, and alkylarylamino), acylamino (in 
cluding alkylcarbonylamino, arylcarbonylamino, carbamoyl 
and ureido), amidino, imino, Sulfhydryl, alkylthio, arylthio. 
thiocarboxylate, Sulfates, Sulfonato, Sulfamoyl, Sulfonamido, 
nitro, trifluoromethyl, cyano, azido, heterocyclyl, or an aro 
matic or heteroaromatic moiety. Heterocyclic groups can also 
be substituted at one or more constituent atoms with, for 
example, a lower alkyl, a lower alkenyl, a lower alkoxy, a 
lower alkylthio, a lower alkylamino, a lower alkylcarboxyl, a 
nitro, a hydroxyl, —CF, or—CN, or the like. 
As used herein, “halo' or “halogen refers to fluoro, 
chloro, bromo, and iodo. “Counterion' is used to represent a 
Small, negatively charged species such as fluoride, chloride, 
bromide, iodide, hydroxide, acetate, and Sulfate. 
"Stable compound' and “stable structure' are meant to 
indicate a compound that is sufficiently robust to survive 
isolation, and as appropriate, purification from a reaction 
mixture, and formulation into an efficacious therapeutic 
agent. 
“Free compound is used herein to describe a compound in 
the unbound state. 
“Extinction coefficient' is a constant used in the Beer 
Lambert Law which relates the concentration of the sub 
stance being measured (in moles) to the absorbance of the 
substance in solution (how well the substance in solution 
blocks light beamed through it from getting out on the other 
side). It is an indicator of how much light a compound absorbs 
at a particular wavelength. 
In the specification, the singular forms also include the 
plural, unless the context clearly dictates otherwise. Unless 
defined otherwise, all technical and scientific terms used 
herein have the same meaning as commonly understood by 
one of ordinary skill in the art to which this invention belongs. 
In the case of conflict, the present specification will control. 
Throughout the description, where compositions are 
described as having, including, or comprising, specific com 
ponents, it is contemplated that compositions also consist 
essentially of or consist of the recited components. Simi 
larly, where methods or processes are described as having, 
including, or comprising specific process steps, the processes 
also consistessentially of, or consist of the recited processing 
steps. Further, it should be understood that the order of steps 
or order for performing certain actions is immaterial so long 
as the invention remains operable. Moreover, two or more 
steps or actions can be conducted simultaneously. 
“Small molecule' is an art-recognized term. In certain 
embodiments, this term refers to a molecule, which has a 
molecular weight of less than about 2000 amu, or less than 
about 1000 amu, and even less than about 500 amu. 
All percentages and ratios used herein, unless otherwise 
indicated, are by weight. 
This application relates, at least in part, to purine-based 
triazoles, and particularly to hydrophobic, Substituted purine 
based triazoles that can selectively inhibit certain protein 
kinases, such as cyclin-dependent kinases (CDKs) (e.g., 
CDK5), and thereby suppress the cell cycle to promote cyto 
protective effects. As discussed in more detail below, certain 
diseases or disorders are mediated by overactivation of 
CDKs, which can result in dysregulation of the cell cycle. The 
hydrophobic, substituted purine-based triazoles of the appli 
cation can inhibit or Suspend the cell cycle machinery and, 
consequently, may be useful in modulating (e.g., Suspending) 
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cell cycle progression to control cell growth and differentia 
tion. In certain aspects, the hydrophobic, Substituted purine 
based triazoles can effectively suppress neuronal toxicity 
induced by amyloid B (AB)-oligomers. 
In an aspect of the application the hydrophobic, Substituted 
purine-based triazole (or analog thereof) can target, decrease, 
or inhibit one or more CDKs that play a role in the regulation 
of the mammalian cell cycle. CDKs that can be inhibited by 
the application can include CDK1, CDK2, CDK3, CDK4. 
CDK5, CDK6, CDK7, CDK8 and CDK9. In one example of 
the application, the hydrophobic, substituted purine-based 
triazole (or analog thereof) can inhibit CDK5. It will be 
appreciated that the hydrophobic, substituted purine-based 
triazole (or analog thereof) can inhibit other protein kinases, 
such as AHR, GSK3beta, ERK, protein kinase C, her2, raf1. 
MEK1, MAP kinase, EGF receptor, PDGF receptor, IGF 
receptor, PI3 kinase, weel kinase, Src, and Abl as well as G 
proteins and polymerases. 
In one embodiment of the application, the hydrophobic, 
Substituted purine-based triazole (or analog thereof) can have 




R-S / N N 
Y-S-C SN R2 
or a pharmaceutically acceptable salt thereof, 
where R is a hydrophobic, substituted or unsubstituted, 
aryl, cyclic, or heterocyclic group; and 
where R and R independently represent Substituents 
Selected from the group consisting of hydrogen, halo 
gen, C1-C4 alkyl, C-C alkenyl, C2-C2a alkynyl, 
Cs-Co aryl, C-C2a alkaryl, C-C2a aralkyl, silyl, 
hydroxyl, sulfhydryl, C-C alkoxy, C-C alkeny 
loxy, C2-C2-alkynyloxy, Cs-Co aryloxy, acyl, C2-C24 
alkylcarbonyl (-CO-alkyl), C-C arylcarbonyl 
(—CO-aryl)), acyloxy (-O-acyl), C-C alkoxycarbo 
nyl (—(CO)—O-alkyl). Co-Co aryloxycarbonyl 
(—(CO)—O-aryl), C-C alkylcarbonato (-O- 
(CO)—O-alkyl). Co-Co arylcarbonato (-O-(CO)— 
O-aryl), carboxy ( COOH), carboxylato ( COO), 
carbamoyl (-(CO)—NH), mono-(C-C alkyl)-Sub 
stituted carbamoyl (—(CO) NH(C-C alkyl)), di 
(C-C alkyl)-substituted carbamoyl (—(CO)—N(C- 
C alkyl)), mono-Substituted arylcarbamoyl 
(—(CO). NH-aryl), thiocarbamoyl (—(CS) NH), 
carbamido ( NH (CO) NH), cyano( CN), iso 
cyano (NC), cyanato ( O CN), isocyanato (ONC), 
isothiocyanato (—S NC), azido ( N=N*—N), 
formyl (—(CO)—H), thioformyl ( (CS)—H), amino 
(—NH), mono- and di-(C-C alkyl)-substituted 
amino, mono- and di-(Cs-Co aryl)-substituted amino, 
C-C alkylamido (-NH-(CO)-alkyl). Co-Co aryla 
mido ( NH (CO)-aryl), imino, alkylimino, 
arylimino, nitro ( NO), nitroso ( NO), sulfonic acid 
(—SO -OH), Sulfonato (—SO-O.), C-C alkyl 
Sulfanyl (-S-alkyl), arylsulfanyl, C-C alkylsulfinyl 
(—(SO)-alkyl), Cs-Co arylsulfinyl (—(SO)-aryl), 
C-C alkylsulfonyl ( -SO-alkyl), Cs-Co arylsulfo 
nyl ( -SO-aryl), phosphono ( P(O)(OH)), phospho 














pho ( PO), and phosphino ( -PH), and where each 
R and R being independently unsubstituted or substi 
tuted where appropriate by one or more —OH, halogen, 
amino or alkyl groups. 
In some embodiments, R can be a fluorinated aryl, cyclic, 
or heterocyclic group. Such as a mono, di, or tri fluorinated 
phenyl, cyopropane, cylcobutane, cyclohexane, pyrrole, pyri 
dine, pyrimidine, pyrazole, triazole, furan, pyran, indazole, or 
furazan. 
In other embodiments, R. and R can each independently 
be a hydrogen, a halogen, C-C alkyl, C-C alkenyl, 
C2-C2-alkynyl, Ca-Cao aryl, C-C2-alkaryl, C-C2a aralkyl, 
or an R. NH-, R. NH-NH , NH R NH or 
R. NH R NH radical, in which Ra represents a 
straight- or branched-chain, Saturated or unsaturated alkyl 
radical, an aryl orcycloalkyl radical or a heterocyclic ring and 
R" represents a straight- or branched-chain, Saturated or 
unsaturated alkylene group or an arylene or cycloalkylene 
group, R and Reach containing 1 to 8 carbon atoms, and 
where each R and R can independently be unsubstituted or 
substituted, where appropriate, by one or more —OH, halo 
gen, amino or alkyl groups. 
In some embodiments, the hydrophobic, substituted 
purine-based triazole or analog thereof can have the follow 
ing formula (II): 
or a pharmaceutically acceptable salt thereof, 
where X is a halogen; 
where n is an integer from 0-5: 
where n is an integer from 1-3: 
where Y is substituted or unsubstituted C-C alkyl, 
C2-C2a alkenyl, C2-C2a alkynyl, Ca-Co aryl, C-C24 
alkaryl, C-C aralky; and C-C fluoroalkyl or C-C, 
perfluoroalkyl. 
where R2 is a hydrogen, a halogen, C1-C4 alkyl, C2-C24 
alkenyl, C2-C alkynyl, Cs-Co aryl, C-C alkaryl, 
C-C aralkyl, or an R. NH-, R. NH-NH-. 
NH R NH or R. NH R NH- radical, in 
which Ra represents a straight- or branched-chain, satu 
rated or unsaturated alkyl radical, an aryl or cycloalkyl 
radical or a heterocyclic ring and R' represents a straight 
or branched-chain, Saturated or unsaturated alkylene 
group or an arylene or cycloalkylene group, R and R' 
each containing 1 to 8 carbon atoms, and where R is 
unsubstituted or Substituted, where appropriate, by one 
or more —OH, halogen, amino or alkyl groups. In one 
example, R is hydrogen, Cl, F, an alkyl or Substituted 
alkyl. 
In some embodiments, the hydrophobic, substituted 
purine-based triazole or analog thereof can have the follow 
ing formula (III): 
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(III) 
Or (). N x- )-- S-C 
2 
or a pharmaceutically acceptable salt thereof, wherein 
where n is an integer from 0-5; and C-C fluoroalkyl or 
C-C perfluoroalkyl 
where R2 is a hydrogen, a halogen, C1-C4 alkyl, C-C24 
alkenyl, C-C alkynyl, C-C aryl, C-C alkaryl, 
C-C aralkyl, or an R. NH , R. NH-NH-, 
NH R NH or R. NH R NH- radical, in 
which R4 represents a straight- or branched-chain, Satu 
rated or unsaturated alkyl radical, an aryl or cycloalkyl 
radical or a heterocyclic ring and R' represents a straight 
or branched-chain, Saturated or unsaturated alkylene 
group or an arylene or cycloalkylene group, R and R' 
each containing 1 to 8 carbon atoms, and where R is 
unsubstituted or Substituted, where appropriate, by one 
or more —OH, halogen, amino or alkyl groups. In one 
example, R is hydrogen, Cl, F, an alkyl or Substituted 
alkyl. 
In another embodiment of the application, the hydropho 
bic, Substituted purine-based triazole or analog thereof can 




| N / N 
x- )- S-C 
or a pharmaceutically acceptable salt thereof, 
where n is an integer from 1-3: 
where Y is substituted or unsubstituted C-C alkyl, 
C2-C2a alkenyl, C2-C2a alkynyl, Ca-Co aryl, C-C24 
alkaryl, C-C2a aralky; and 
where R is a hydrogen, a halogen, C-C alkyl, C-C, 
alkenyl, C2-C alkynyl, Cs-Co aryl, C-C alkaryl, 
C-C aralkyl, or an R. NH , R. NH-NH-, 
NH R NH- or R. NH R NH- radical, in 
which R4 represents a straight- or branched-chain, Satu 
rated or unsaturated alkyl radical, an aryl or cycloalkyl 
radical or a heterocyclic ring and R' represents a straight 
or branched-chain, Saturated or unsaturated alkylene 
group or an arylene or cycloalkylene group, R and R' 
each containing 1 to 8 carbon atoms, and where R is 
unsubstituted or Substituted, where appropriate, by one 
or more —OH, halogen, amino or alkyl groups. In one 














In another embodiment of the application, the hydropho 
bic, Substituted purine-based triazole or analog thereof can 




N Y. 2 N 
story / -Q 
N 
R2 
or a pharmaceutically acceptable salt thereof, 
where n is an integer from 1-3; and C-C fluoroalkyl or 
C-C perfluoroalkyl. 
where Y is substituted or unsubstituted C-C alkyl, 
C2-C2a alkenyl, C2-C2a alkynyl, Ca-Co aryl, C-C24 
alkaryl, C-C2a aralky; 
where R is a hydrogen, a halogen, C-C alkyl, C-C, 
alkenyl, C2-C alkynyl, Cs-Co aryl, C-C alkaryl, 
C-C aralkyl, or an R. NH , R. NH-NH-, 
NH R NH- or R. NH R NH- radical, in 
which R represents a straight- or branched-chain, Satu 
rated or unsaturated alkyl radical, an aryl or cycloalkyl 
radical or a heterocyclic ring and R' represents a straight 
or branched-chain, Saturated or unsaturated alkylene 
group or an arylene or cycloalkylene group, R and R' 
each containing 1 to 8 carbon atoms, and where R is 
unsubstituted or Substituted, where appropriate, by one 
or more —OH, halogen, amino or alkyl groups. In one 
example, R is hydrogen, Cl, F, an alkyl or Substituted 
alkyl. 
In yet another embodiment of the application, the hydro 
phobic, substituted purine-based triazole or analog thereof 







or a pharmaceutically acceptable salt thereof, 
where n is an integer from 1-3: 
where Y is substituted or unsubstituted C-C alkyl, 
C-C alkenyl, C-C alkynyl, C-Co aryl, C-C, 
alkaryl, C-C aralky; and C-C fluoroalkyl or C-C 
perfluoroalkyl. 
where Ro and R are each independently a hydrogen or a 
halogen; and 
where R is a halogen atom, C-C alkyl, C-C alkenyl, 
C2-C2a alkynyl, Cs-Co aryl, C-C2a alkaryl, C-C24 
aralkyl, or an R. NH , R. NH NH , NH, 
R" NH or R. NH R NH radical, in which 
R represents a straight- or branched-chain, Saturated or 
unsaturated alkyl radical, an aryl or cycloalkyl radical or 
a heterocyclic ring and R' represents a straight- or 
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branched-chain, Saturated or unsaturated alkylene group 
or an arylene or cycloalkylene group, Ra and R' each 
containing 1 to 8 carbon atoms, and where R is unsub 
stituted or substituted, where appropriate, by one or 
more —OH, halogen, amino or alkyl groups. In one 
example, R is hydrogen, Cl, F, an alkyl or Substituted 
alkyl. 
In another embodiment of the application, the hydropho 
bic, Substituted purine-based triazole or analog thereof can 




XS-N, / N Q- y- -Q 
or a pharmaceutically acceptable salt thereof, 
where R is hydrogen or a halogen; 
where R is O, N or S; 
where n is an integer from 1-3: 
where Y is substituted or unsubstituted C-C alkyl, 
C2-C2a alkenyl, C2-C2a alkynyl, Ca-Co aryl, C-C24 
alkaryl, C-C aralky; and C-C fluoroalkyl or C-C, 
perfluoroalkyl. 
where R is a halogenatom, C-C alkyl, C-C alkenyl, 
C-C alkynyl, C-Co aryl, C-C alkaryl, C-C, 
aralkyl, or an R. NH , R. NH NH NH 
R" NH- or R. NH R NH- radical, in which 
R represents a straight- or branched-chain, Saturated or 
unsaturated alkyl radical, an aryl or cycloalkyl radical or 
a heterocyclic ring and R' represents a straight- or 
branched-chain, Saturated or unsaturated alkylene group 
or an arylene or cycloalkylene group, Ra and R' each 
containing 1 to 8 carbon atoms, and where R is unsub 
stituted or substituted, where appropriate, by one or 
more —OH, halogen, amino or alkyl groups. In one 
example, R is hydrogen, Cl, F, an alkyl or Substituted 
alkyl. 
In still other embodiments, the substituted purine-based 
triazoles can be selected from compounds III-VII, where n is 
an integer from 0-5, where R is a hydrogen, a halogen (e.g., 
Cl or F), an alkyl or substituted alkyl; where R. R. Rare 
each independently a hydrogen or a halogen; and where R. 
is O, N or S. 
It will be readily appreciated by those of skill in the art that 
depending on the Substituents, the purine analogs of the 
present invention can be a racemic mixture or either of a pair 
of diastereomers or enantiomers. 
The hydrophobic, substituted purine-based triazoles (or 
analogs thereof) can be synthesized using click chemistry. 
Click chemistry is a convenient way for tethering halogenated 
and variously substituted aryl moieties to purine-derived 
alkynes (see, e.g., Spiteri, C. et al., Angew. Chem. Int. Ed. 
49:31-33, 2010; and Tron, G C et al., Med. Res. Rev. 28:278 
308, 2008). For instance, click chemistry can be used to 
couple one or more hydrophobic, halogen-substituted aryl 
moieties to a purine-derived alkyne through 1,2,3-triazole 
linkage(s). Introduction of a fluorinated aryl group, for 
example, can improve the therapeutic efficiency of the Sub 













the hydrogen bonding interactions with the fluorines at the 
enzyme active site. Additionally, the halogen-substituted aryl 
moiety or moieties that form part of the substituted purine 
based triazoles impart the substituted purine-based triazoles 
with sufficient hydrophobicity to facilitate entry of the sub 
stituted purine-based triazoles into and across cell mem 
branes. 
In one example of the application, a triazole and its fluori 
nated derivatives can be prepared by a Cu(I)-catalyzed 1,3- 
dipolar cycloaddition reaction of the corresponding alkyne 
and azide substrates. As shown below in Scheme 1, synthesis 
can begin with the reaction of 2,6-dichloropurine (Compound 
3) with benzylamine () as described, for example, by 
Oumata, N. et al., Org. Process Res. Dev. 13:641-644 (2009). 
Using the conditions set forth in the Example below, the 
reaction can be completed in about 15 minutes at about 60°C. 
2-chloro-6-benzylaminopurine (Compound 4) can be prop 
argylated using propargyl bromide in DMSO under mild con 
ditions to yield 2-chloro-6-benzylamino-9-(2-propynyl) 
purine (Compound 5). The Cu(I)-catalyzed azide-alyne click 
reaction (as described, for example, by Amblard, F. et al., 
Chem. Rev. 109:4207-4220, 2009) of 2-chloro-6-benzy 
lamino-9-(2-propynyl) purine (Compound 5) with fluori 
nated benzyl azides (which can be prepared in situ from their 
corresponding benzyl bromides) can then yield 1,4-disubsti 
tuted triazoles or, more specifically, 2-chloro-6-benzy 
lamino-9-1-(2-fluorobenzyl)-1H-1,2,3-triazol-4-yl-methyl 
purine (Compound 7), 2-chloro-6-benzylamino-9-1-(2,6- 
difluorobenzyl)-1H-1,2,3-triazol-4-yl-methylpurine 
(Compound 8), and 2-chloro-6-benzylamino-9-1-(pen 
tafluorobenzyl)-1H-1,2,3-triazol-4-yl-methylpurine (Com 
pound 9). 
Scheme 1. Synthesis of purine-based fluoroaryl triazoles: 
C 
N-1N N ( --> 
2 N NY net 
3 
HN 
N-1N b N -e- {ll 2 N n° no 
4 
HN 
NS1 N C N e 
N1S2 
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-continued 
N HN / \ r 
Fr— N-M \, /SN/ N NR M N2 N C 
6; n = 0 
7; n = 1; o-fluoro 
8; n = 2; 2,6-difluoro 
9 n = 5 
reagents and conditions: benzylamine/EtsN/n-BuOH, 60°C/15 min, 95%; propargyl 
bromide K2CO3DMSO, 0°C. 1 h, 80%; fluorophenylmethyl bromide (or 
phenylmethyl bromide), sodium azide?Cu(I)BriEtNDMSO, RT/30 min, 80-89%. 
The substituted purine-based triazoles described herein 
can be incorporated into a variety of formulations for thera 
peutic administration. More particularly, the substituted 
purine-based triazoles can beformulated into pharmaceutical 
compositions by combination with appropriate, pharmaceu 
tically acceptable carriers or diluents, and may be formulated 
into preparations in Solid, semi-solid, liquid orgaseous forms, 
Such as tablets, capsules, pills, powders, granules, dragees, 
gels, slurries, ointments, Solutions, Suppositories, injections, 
inhalants and aerosols. As such, administration of the Substi 
tuted purine-based triazoles can be achieved in various ways, 
including oral, buccal, rectal, parenteral, intraperitoneal, 
intradermal, transdermal, intracheal, etc., administration. 
Moreover, the substituted purine-based triazoles can be 
administered in a local rather than systemic manner, for 
example via injection of the compound directly into a tissue 
being treated, often in a depot or Sustained release formula 
tion. 
In addition, the substituted purine-based triazoles can be 
administered in a targeted drug delivery system, for example, 
in a liposome coated with tissue or cell-specific antibody. 
Such liposomes will be targeted to and taken up selectively by 
the tissue or cell. 
Formulations for use in the application are found in Rem 
ington's Phannaceutical Sciences (Mack Publishing Com 
pany, Philadelphia, Pa., 17th ed. (1985)), which is incorpo 
rated herein by reference. Moreover, for a brief review of 
methods for drug delivery, see, Langer, Science 249:1527 
1533 (1990), which is incorporated herein by reference. The 
pharmaceutical compositions described herein can be manu 
factured in a manner that is known to those of skill in the art, 
i.e., by means of conventional mixing, dissolving, granulat 
ing, dragee-making, levigating, emulsifying, encapsulating, 
entrapping or lyophilizing processes. The following methods 
and excipients are merely exemplary and are in no way lim 
iting. 
For injection, the substituted purine-based triazoles can be 
formulated into preparations by dissolving, Suspending or 
emulsifying them in an aqueous or nonaqueous solvent. Such 
as Vegetable or other similar oils, synthetic aliphatic acid 
glycerides, esters of higher aliphatic acids or propylene gly 
col; and if desired, with conventional additives Such as solu 
bilizers, isotonic agents, Suspending agents, emulsifying 
agents, stabilizers and preservatives. The Substituted purine 
based triazoles may be formulated in aqueous solutions, such 
as in physiologically compatible buffers such as Hanks’s 













transmucosal administration, penetrants appropriate to the 
barrier to be permeated are used in the formulation. Such 
penetrants are generally known in the art. 
For oral administration, the substituted purine-based tria 
Zoles can be formulated by combining with pharmaceutically 
acceptable carriers that are well known in the art. Such car 
riers enable the compounds to be formulated as tablets, pills, 
dragees, capsules, emulsions, lipophilic and hydrophilic Sus 
pensions, liquids, gels, syrups, slurries, Suspensions and the 
like, for oral ingestion by a patient to be treated. Pharmaceu 
tical preparations for oral use can be obtained by mixing the 
compounds with a solid excipient, optionally grinding a 
resulting mixture, and processing the mixture of grammes, 
after adding suitable auxiliaries, if desired, to obtaintablets or 
dragee cores. Suitable excipients are, in particular, fillers such 
as Sugars, including lactose, Sucrose, mannitol, or Sorbitol; 
cellulose preparations such as, for example, maize starch, 
wheat starch, rice starch, potato starch, gelatin, gum traga 
canth, methyl cellulose, hydroxypropylmethyl-cellulose, 
Sodium carboxymethylcellulose, and/or polyvinylpyrroli 
done (PVP). If desired, disintegrating agents may be added, 
Such as the cross-linked polyvinyl pyrrolidone, agar, or alg 
inic acid or a salt thereof Such as Sodium alginate. 
Dragee cores can be provided with Suitable coatings. For 
this purpose, concentrated Sugar Solutions may be used, 
which may optionally contain gum arabic, talc, polyvinyl 
pyrrolidone, carbopol gel, polyethylene glycol, and/or tita 
nium dioxide, lacquer Solutions, and Suitable organic solvents 
or solvent mixtures. Dyestuffs or pigments may be added to 
the tablets or dragee coatings for identification or to charac 
terize different combinations of active compound doses. 
Pharmaceutical preparations which can be used orally 
include push-fit capsules made of gelatin, as well as Soft, 
sealed capsules made of gelatin and a plasticizer, Such as 
glycerol or Sorbitol. The push-fit capsules can contain the 
active ingredients in admixture with filler Such as lactose, 
binders such as starches, and/or lubricants such as talc or 
magnesium Stearate and, optionally, stabilizers. In soft cap 
Sules, the active compounds may be dissolved or Suspended in 
Suitable liquids, such as fatty oils, liquid paraffin, or liquid 
polyethylene glycols. In addition, stabilizers may be added. 
All formulations for oral administration should be in dosages 
Suitable for Such administration. 
For buccal administration, the compositions may take the 
form of tablets or lozenges formulated in conventional man 
. 
For administration by inhalation, the compounds described 
herein are conveniently delivered in the form of an aerosol 
spray presentation from pressurized packs or a nebulizer, with 
the use of a Suitable propellant, e.g., dichlorodifluo 
romethane, trichlorofluoromethane, dichlorotetrafluoroet 
hane, carbon dioxide or other Suitable gas, or from propellant 
free, dry-powder inhalers. In the case of a pressurized aerosol 
the dosage unit may be determined by providing a valve to 
deliver a metered amount. Capsules and cartridges of e.g., 
gelatin for use in an inhaler or insufflator may be formulated 
containing a powder mix of the compound and a suitable 
powder base. Such as lactose or starch. 
The substituted purine-based triazoles may be formulated 
for parenteral administration by injection, e.g., by bolus 
injection or continuous infusion. Formulations for injection 
may be presented in unit dosage form, e.g., in ampules or in 
multidose containers, with an added preservative. The com 
positions may take such forms as Suspensions, Solutions or 
emulsions in oily or aqueous vehicles, and may contain for 
mulatory agents such as Suspending, stabilizing and/or dis 
persing agents. 
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Pharmaceutical formulations for parenteral administration 
include aqueous solutions of the active compounds in water 
soluble form. Additionally, Suspensions of the active com 
pounds may be prepared as appropriate oily injection Suspen 
sions. Suitable lipophilic solvents or vehicles include fatty 
oils such as sesame oil, or synthetic fatty acid esters. Such as 
ethyl oleate or triglycerides, or liposomes. Aqueous injection 
Suspensions may contain Substances which increase the vis 
cosity of the Suspension, such as Sodium carboxymethyl cel 
lulose, Sorbitol, or dextran. Optionally, the Suspension may 
also contain stabilizers or agents, which increase the solubil 
ity of the compounds to allow for the preparation of highly 
concentrated Solutions. Alternatively, the Substituted purine 
based triazoles may be in powderform for constitution with a 
Suitable vehicle, e.g., sterile pyrogen-free water, before use. 
The substituted purine-based triazoles may also be formu 
lated in rectal compositions such as Suppositories or retention 
enemas, e.g., containing conventional Suppository bases Such 
as cocoa butter, carbowaxes, polyethylene glycols or other 
glycerides, all of which melt at body temperature, yet are 
solidified at room temperature. 
In addition to the formulations described previously, the 
substituted purine-based triazoles may also be formulated as 
a depot preparation. Such long acting formulations may be 
administered by implantation (for example Subcutaneously or 
intramuscularly) or by intramuscular injection. Thus, for 
example, the substituted purine-based triazoles may be for 
mulated with suitable polymeric or hydrophobic materials 
(for example as an emulsion in an acceptable oil) or ion 
exchange resins, or as sparingly soluble derivatives, for 
example, as a sparingly soluble salt. 
Alternatively, other delivery systems for hydrophobic sub 
stituted purine-based triazoles may be employed. Liposomes 
and emulsions are well known examples of delivery vehicles 
or carriers for hydrophobic drugs. Certain organic solvents 
Such as dimethylsulfoxide also may be employed, although 
usually at the cost of greater toxicity. 
Additionally, the substituted purine-based triazoles may be 
delivered using a Sustained-release system, such as semiper 
meable matrices of Solid hydrophobic polymers containing 
the therapeutic agent. Various types of Sustained-release 
materials have been established and are well known by those 
skilled in the art. Sustained-release capsules may, depending 
on their chemical nature, release the compounds for a few 
weeks up to over 100 days. 
The pharmaceutical compositions also may comprise Suit 
able Solid or gel phase carriers or excipients. Examples of 
Such carriers or excipients include but are not limited to 
calcium carbonate, calcium phosphate, various Sugars, 
starches, cellulose derivatives, gelatin, and polymers such as 
polyethylene glycols. 
Pharmaceutical compositions can also include composi 
tions wherein the substituted purine-based triazoles are con 
tained in a therapeutically effective amount. The amount of 
composition administered will, of course, be dependent on 
the subject being treated, on the subjects weight, the severity 
of the affliction, the manner of administration and the judg 
ment of the prescribing physician. Determination of an effec 
tive amount is well within the capability of those skilled in the 
art, especially in light of the detailed disclosure provided 
herein. 
For any compound used in a method described herein, a 
therapeutically effective dose can be estimated initially from 
cell culture assays. For example, a dose can be formulated in 
animal models to achieve a circulating concentration range 
that includes the ICso as determined in cell culture (i.e., the 













culture), or the ICoo as determined in cell culture (i.e., the 
concentration of compound that is lethal to 100% of a cell 
culture). Such information can be used to more accurately 
determine useful doses in humans. Initial dosages can also be 
estimated from in vitro or in vivo data. 
Initial dosages can also be formulated by comparing the 
effectiveness of the compounds described herein in cell cul 
ture assays with the effectiveness of known drugs. For 
instance, initial dosages can be formulated by comparing the 
effectiveness of the substituted purine-based triazoles 
described herein in cell culture assays with the effectiveness 
of a CDK inhibitor, such as Roscovitine. In this method, an 
initial dosage can be obtained by multiplying the ratio of 
effective concentrations obtained in cell culture assay for the 
substituted purine-based triazoles described herein and a 
known CDK inhibitor by the effective dosage of the known 
CDK inhibitor. For example, if a substituted purine-based 
triazole described herein is twice as effective in cell culture 
assay than Roscovitine, an initial effective dosage of the 
substituted purine-based triazoles would be one-half the 
known dosage for Roscovitine. Using these initial guidelines 
one having ordinary skill in the art could determine an effec 
tive dosage in humans. 
Moreover, toxicity and therapeutic efficacy of the com 
pounds described herein can be determined by standard phar 
maceutical procedures in cell cultures or experimental ani 
mals, e.g., by determining the LDs (the dose lethal to 50% of 
the population) and the EDs (the dose therapeutically effec 
tive in 50% of the population). The dose ratio between toxic 
and therapeutic effect is the therapeutic index and can be 
expressed as the ratio between LDs and EDso. Substituted 
purine-based triazoles, which exhibit high therapeutic indices 
are preferred. The data obtained from these cell culture assays 
and animal studies can be used in formulating a dosage range 
that is not toxic for use in human. The dosage of Such com 
pounds lies preferably within a range of circulating concen 
trations that include the EDs with little or no toxicity. The 
dosage may vary within this range depending upon the dosage 
form employed and the route of administration utilized. The 
exact formulation, route of administration and dosage can be 
chosen by the individual physician in view of the patients 
condition. (See, e.g., Finglet al., 1975. In: The Pharmaco 
logical Basis of Therapeutics, Ch. 1, p. 1). 
Dosage amount and interval may be adjusted individually 
to provide plasma levels of the active compound, which are 
sufficient to maintain therapeutic effect. Usual patient dos 
ages for oral administration range from about 50-2000 
mg/kg/day, commonly from about 100-1000 mg/kg/day, 
preferably from about 150-700 mg/kg/day and most prefer 
ably from about 250-500 mg/kg/day. Preferably, therapeuti 
cally effective serum levels will beachieved by administering 
multiple doses each day. In cases of local administration or 
selective uptake, the effective local concentration of the drug 
may not be related to plasma concentration. One having skill 
in the art will be able to optimize therapeutically effective 
local dosages without undue experimentation. 
The substituted purine-based triazoles described herein 
can be used either in vitro or in vivo for a variety of purposes. 
As discussed previously, in Some embodiments of the appli 
cation, the Substituted purine-based triazoles can be used to 
inhibit protein kinases, G proteins and polymerases. Protein 
kinases which can be inhibited using the purine-based triaz 
oles described herein include, but are not limited to, cyclin 
dependent kinases (CDKs), MAP kinases (p38, ERK), 
(MAPK/MEK/MEKK), cAMP-dependent kinase, c-GMP 
dependent kinase, Calmodulin-dependent kinase, CSK 
(C-src like kinase) pp 60 c-Src, myosin light chain kinase, 
US 8,969,556 B2 
23 
JNK kinase, IKB kinase, Protein kinase C, etc. In a presently 
preferred embodiment, the protein kinase is a CDK. Such 
CDKs include CDK1 (or, interchangeably, CDC2) and 
CDK2-CDK8. G proteins that can be inhibited using the 
substituted purine-based triazoles include, but are not limited 
to, GTP binding proteins. Polymerases, which can be inhib 
ited using the purine analogs of the present invention include, 
but are not limited to, DNA polymerase a, DNA polymerase 
6, DNA topoisomerase I, topoisomerase II, phosphatases, 
telomerases, etc. Other protein kinases, G proteins and poly 
merases which can be inhibited using the substituted purine 
based triazoles described herein will be known to those of 
skill in the art. 
In other embodiments, the substituted purine-based triaz 
oles can be used in a method for inhibiting at least one CDK 
in a subject. Due to the key role of CDKs in regulating the cell 
cycle and cellular proliferation, the substituted purine-based 
triazoles (or analogs thereof) disclosed herein may act as 
reversible cytostatic agents, which may be useful in the treat 
ment of any disease process featuring abnormal cell cycle or 
cellular proliferation, including, but not limited to, abnormal 
stimulation of endothelial cells (e.g., atherosclerosis), neo 
plastic disorders, Solid tumors and tumor metastasis, benign 
tumors, for example, hemangiomas, acoustic neuromas, neu 
rofibromas, trachomas, and pyogenic granulomas, cancer, 
vascular malfunctions, abnormal wound healing, inflamma 
tory and immune disorders, Bechet's disease, gout or gouty 
arthritis, abnormal angiogenesis accompanying, for example, 
rheumatoid arthritis, psoriasis, alopecia, diabetic retinopathy, 
other ocular angiogenic diseases, such as retinopathy of pre 
maturity (retrolental fibroplastic), macular degeneration, cor 
neal graft rejection, neuroscular glaucoma and Oster Webber 
syndrome, fungal, parasitic and viral infections, such as 
cytomegaloviral infections, neurological disorders, stroke, 
neurofibromatosis, endotoxic shock, hypertrophic scar for 
mation, inflammatory bowel disease, transplant rejection, 
vascular Smooth muscle cell proliferation associated with 
atherosclerosis, pulmonary fibrosis, arthritis, glomerulone 
phritis, restenosis following angioplasty or vascular Surgery, 
and other post-Surgical Stenosis and restenosis. 
In one specific embodiment, the substituted purine-based 
triazoles can be administered to a Subject to treat a prolifera 
tive disorder of the subject. The proliferative disorder 
described herein can include, for example cardiovascular dis 
orders, such as restenosis and cardiomyopathy, neoplastic 
disorders, auto-immune disorders, such as glomerulonephri 
tis and rheumatoid arthritis, dermatological disorders such as 
psoriasis, anti-inflammatory, anti-fungal, antiparasitic disor 
ders, such as malaria, emphysema and alopecia. In these 
disorders, the substituted purine-based triazoles described 
herein may induce apoptosis or maintain stasis within the 
desired cells as required. 
The substituted purine-based triazoles described herein 
can inhibit any of the steps or stages in the cell cycle, for 
example, formation of the nuclear envelope, exit from the 
quiescent phase of the cell cycle (GO), G1 progression, chro 
mosome decondensation, nuclear envelope breakdown, 
START, initiation of DNA replication, progression of DNA 
replication, termination of DNA replication, centroSome 
duplication, G2 progression, activation of mitotic or meiotic 
functions, chromosome condensation, centrosome separa 
tion, microtubule nucleation, spindle formation and function, 
interactions with microtubule motor proteins, chromatid 
separation and segregation, inactivation of mitotic functions, 
formation of contractile ring, and cytokinesis functions. In 
particular, the Substituted purine-based triazoles may influ 













mation of replication complexes, replication licensing, phos 
phorylation or other secondary modification activity, 
proteolytic degradation, microtubule binding, actin binding, 
septin binding, microtubule organising centre nucleation 
activity and binding to components of cell cycle signalling 
pathways. 
In one embodiment, the proliferative disorder can be a 
neoplastic disorder. By way of example, neoplastic disorders 
treatable by the compounds described herein can include, but 
are not limited to: carcinoma, including that of the bladder, 
breast, colon, kidney, liver, lung, including Small cell lung 
cancer, esophagus, gall bladder, ovary, pancreas, stomach, 
cervix, thyroid, prostate, and skin, including squamous cell 
carcinoma; hematopoietic tumors of lymphoid lineage, 
including leukemia, acute lymphocytic leukemia, acute lym 
phoblastic leukemia, B-cell lymphoma, T-cell lymphoma, 
Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, hairy cell 
lymphoma, and Burkett's lymphoma; hematopoietic tumors 
of myeloid lineage, including acute and chronic myelogenous 
leukemias, myelodysplastic syndrome, and promyelocytic 
leukemia; tumors of mesenchymal origin, including fibrosa 
rcoma and rhabdomyosarcoma; tumors of the central and 
peripheral nervous system, including astrocytoma, neuro 
blastoma, glioma, and Schwannomas; and other tumors, 
including melanoma, seminoma, teratocarcinoma, osteosar 
coma, Xenoderoma pigmentosum, keratoctanthoma, thyroid 
follicular cancer, and Kaposi's sarcoma. 
Neoplastic disorders, such as cancer are typically charac 
terized by abnormal cell division as a result of dysfunctional 
signaling cascades and/or checkpoint control within the cell 
cycle. For example, the first stage of the cell cycle, which is 
mediated by a highly controlled kinase family, consists of a 
cascade of protein phosphorylations that relay a cell from one 
stage to the next. The second stage is a set of checkpoints that 
monitor completion of critical events and delay progression 
to the next stage, if necessary. CDKs are critically important 
in the first stage, and their overactivity can result in disruption 
of the cell cycle and progression to uncontrolled cell growth. 
By inhibiting at least one CDK in the subject, the cell cycle in 
neoplastic or potentially neoplastic cells can be maintained or 
suspended so that the cells do not become hyperproliferative. 
In another embodiment, the substituted purine-based tria 
Zoles can be administered to a subject to treat a neurological 
or neurodegenerative disorder including central nervous sys 
tem disorders or peripheral nervous system disorders. 
Examples of neurological disorders treated by the com 
pounds and compositions described herein can include, but 
are not limited to, Alzheimer's disease, Parkinson's disease, 
Huntington's disease, amyotrophic lateral Sclerosis, multiple 
sclerosis, elderly dementia, Tay-Sachs disease, Sandhoffs 
disease, Hurler's syndrome, Krabbe's disease, central or 
peripheral nervous system injury, epilepsy, multiple Sclerosis, 
central or peripheral nervous system trauma, stroke, Asperger 
syndrome, Autism, Attention deficit hyperactivity disorder 
(ADHD), Cerebral palsy, Dyslexia, seizures, Mild Cognitive 
Impairment (MCI), retinitis pigmentosa, spinal muscular 
atrophy, motor neuron disease, bipolar disorder, cerebellar 
degeneration or age associated memory impairment. 
In one example, the Substituted purine-based triazoles 
described herein can be used to treat a subject suffering from 
a neurological disorder mediated by AB, Such as Alzheimer's 
disease. The Substituted purine-based triazoles can be can 
administered at a therapeutically effective amount in a phar 
maceutical composition that includes the purine-based triaz 
ole and a pharmaceutical carrier. The therapeutically effective 
amount of the pharmaceutical composition can be adminis 
tered to the Subject via an appropriate route. Upon adminis 
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tration to the subject, the substituted purine-based triazole can 
readily traverse neuronal cell membranes as a result of the 
compounds hydrophobic nature. The substituted purine 
based triazole can then selectively inhibit CDK5 due to the 
hydrogen bonding interactions at the enzyme’s active site 
Inhibition of CDK5 can consequently prevent or mitigate 
tau-hyperphosphorylation, increase levels of synaptic mark 
ers, and Suppress or Suspend the neuronal cell cycle to pro 
mote neuronal Survival. 
In another embodiment, the substituted purine-based tria 
Zoles can be used as an antiviral agent. For example, the 
substituted purine-based triazoles described herein can be 
used in the preparation of a medicament for treating a viral 
disorder, such as human cytomegalovirus (HCMV), herpes 
simplex virus type 1 (HSV-1), human immunodeficiency 
virus type 1 (HIV-1), and varicella Zoster virus (VZV). 
In a more preferred embodiment, the substituted purine 
based triazoles can be administered at an amount effective to 
inhibit one or more of the host cell CDKs involved in viral 
replication (Wang D, De la Fuente C, Deng L, Wang L, 
Zilberman I, Eadie C, Healey M, Stein D, Denny T. Harrison 
L E. Meijer L. Kashanchi F Inhibition of human immunode 
ficiency virus type 1 transcription by chemical cyclin-depen 
dent kinase inhibitors. J. Virol. 2001: 75: 7266-7279). As 
defined herein, an anti-viral effect within the scope of the 
present invention may be demonstrated by the ability to 
inhibit at least one CDK. 
In a particular embodiment, the substituted purine-based 
triazoles can be used in the treatment of a viral disorder which 
is CDK dependent or sensitive. CDK dependent disorders are 
associated with an above normal level of activity of one or 
more CDK enzymes. Such disorders can be associated with 
an abnormal level of activity of CDK. A CDKsensitive dis 
order is a disorder in which an aberration in the CDKlevel is 
not the primary cause, but is downstream of the primary 
metabolic aberration. In such scenarios, CDK can be said to 
be part of the sensitive metabolic pathway and CDK inhibi 
tors may therefore be active in treating Such disorders. 
Another aspect of the invention relates to the use of the 
Substituted purine-based triazoles, or pharmaceutically 
acceptable salts thereof, in the preparation of a medicament 
for treating diabetes. In a particular embodiment, the diabetes 
is type II diabetes. 
GSK3 is one of several protein kinases that phosphorylate 
glycogen synthase (GS). The stimulation of glycogen synthe 
sis by insulin in skeletal muscle results from the dephospho 
rylation and activation of G.S. GSK3's action on GS thus 
results in the latter's deactivation and thus suppression of the 
conversion of glucose into glycogen in muscles. 
Type II diabetes (non-insulin dependent diabetes mellitus) 
is a multi-factorial disease. Hyperglycaemia is due to insulin 
resistance in the liver, muscles, and other tissues, coupled 
with impaired secretion of insulin. Skeletal muscle is the 
main site for insulin-stimulated glucose uptake, there it is 
either removed from circulation or converted to glycogen. 
Muscle glycogen deposition is the main determinant in glu 
cose homeostasis and type II diabetics have defective muscle 
glycogen storage. There is evidence that an increase in GSK3 
activity is important in type II diabetes Chen, Y. H.; Hansen, 
L.; Chen, M. X., Bjorbaek, C.; Vestergaard, H.; Hansen, T.; 
Cohen, P.T.: Pedersen, O. Diabetes, 1994, 43, 1234. Further 
more, it has been demonstrated that GSK3 is over-expressed 
in muscle cells of type II diabetics and that an inverse corre 
lation exists between skeletal muscle GSK3 activity and insu 
lin action Nikoulina, S. E.; Ciaraldi, T. P.; Mudaliar, S.; 
Mohideen, P.; Carter, L.; Henry, R. R. Diabetes, 2000, 49, 













triazoles described herein is therefore of therapeutic signifi 
cance in the treatment of diabetes, particularly type II, and 
diabetic neuropathy. 
Yet another embodiment of the application relates to the 
use of the substituted purine-based triazoles in the prepara 
tion of a medicament for treating alopecia. Hair growth is 
controlled by the Wnt signalling pathway, in particular Wnt 
3. In tissue-culture model systems of the skin, the expression 
of non-degradable mutants of B-catenin leads to a dramatic 
increase in the population of putative stem cells, which have 
greater proliferative potential Zhu, A. J.; Watt, F. M. Devel 
opment, 1999, 126, 2285. This population of stem cells 
expresses a higher level of non-cadherin-associated beta.- 
catenin DasGupta, R.; Fuchs, E. Development, 1999, 126, 
4557, which may contribute to their high proliferative poten 
tial. Moreover, transgenic mice overexpressing a truncated 
.beta.-catenin in the skin undergo de novo hair-follicle mor 
phogenesis, which normally is only established during 
embryogenesis. The ectopic application of GSK3 inhibitors 
may therefore be therapeutically useful in the treatment of 
baldness and in restoring hair growth following chemo 
therapy-induced alopecia. A further aspect of the application 
therefore relates to a method of treating a GSK3-dependent 
disorder, said method comprising administering to a subject 
in need thereof, substituted purine-based triazole, or a phar 
maceutically acceptable salt thereof, as defined above in an 
amount sufficient to inhibit GSK3. 
The following example is for the purpose of illustration 
only and is not intended to limit the scope of the claims, which 
are appended hereto. 
EXAMPLE 
In this example, we synthesized a series of fluorinated 
purine-based triazoles and assayed their protective effect 
against Af-induced neurotoxicity in hippocampal slice cul 
tures. We reasoned that a fluoroaryl group distant from the 
nucleoside moiety, through optimal hydrophobic interactions 
at the enzyme active site, could impart selective CDK5 inhibi 
tory effect, effectively causing neuronal cell cycle Suppres 
S1O. 
Selective inhibition of CDK5/p25 over CD5/p35 and other 
CDK kinases is a desired goal for the treatment of a number 
of CDK dependent disorders, including neurological disor 
ders, such as Alzheimer's disease and proliferative disorders, 
Such as cancer. Roscovitine is currently undergoing clinical 
trials as kinase inhibitor in AD, although it is not a selective 
inhibitor of CDK5. Similarly, a flavone-derived compound, 
Flavopiridol has also been shown to be effective as a broad 
spectrum CDK inhibitor. Perhaps due to this nonspecificity to 
selective CDKs, it is more cytotoxic and has other harmful 
effects. It is therefore desirable to design selective CDK 
inhibitors that show neuroprotective effects, without atten 
dant harmful side effects. We anticipated that modulating the 
hydrophobicity effect of the compounds by attaching the 
fluoroaryl rings to the Roscovitine analogues through 1,2,3- 
triazole linkage might make these compounds selective 
inhibitors of CDKs. We adopted Sharpless-Huisgen’s Click 
chemistry as a convenient technique for tethering fluorinated 
and variously substituted aryl moieties to purine derived 
alkynes, and investigated the neuroprotective effects of these 
fluoroaryl substituted purine based 1,2,3-triazoles along with 
those of Flavopiridol (1) and Roscovitine (2) for AD and 
related neurological diseases. 
In this Example, we used a convenient assay for neuronal 
cell death, which was induced by incubation with A oligo 
mers in hippocampal slice cultures. The binding of propidium 
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iodide (PI) with DNA of dead cells gives characteristic fluo 
rescence that could be followed by fluorescence microscopy. 
Since PI is impermeable to live cell membranes, the observed 
fluorescence is indicative of the extent of dead cell popula 
tions. Using this technique, we have found that incubation of 
hippocampal neuronal cells with A? results in significant 
neuronal cell death after a duration of 48 h (FIG. 1). 
Materials and Methods 
Benzylamine (>99.5%), 1-butanol (anhydrous, 99.8%), 
benzyl bromide (reagent grade, 98%) triethylamine 
(>99.5%), dimethyl sufoxide (ACS reagent, >99.9%), potas 
sium carbonate (ACS reagent, >99.9%), Copper(I)bromide 
(98%), 2-flurobenzyl bromide (98%), 2,6-difluorobenzylbro 
mide (97%), pentafluorobenzylbromide (99%), and 2,6- 
dichloropurine (97%) were obtained from Aldrich and used 
as received. 
"H NMR spectra (400 MHz), ''C NMR spectra (100 
MHz), and F NMR spectra (376 MHz) were obtained on a 
Varian Inova 400 MHz spectrometer in DMSO-desolutions. 
'F NMR spectra were referenced to CFCs (8'F=0), and H, 
and 'C NMR were referenced to the residual solvent signals 
or internal tetramethylsilane. EI/MS was obtained using solid 
probe on a Hewlett Packard HPs 5890 GC/MS instrument. 
Computational Methodology 
The CDK5 protein structure was obtained from its Rosco 
vitine co-crystal PDB entry, “1 UNL, and minimized using 
Dreiding force-field. This protein structure was used to first 
identify potential ligand binding regions as follows: The 
entire protein was scanned for potential binding regions with 
no assumption on the binding site. The entire molecular Sur 
face of the predicted Structure is mapped and spheres repre 
senting the empty volume of the protein are generated (using 
the Sphgen program in DOCK4.0 suite of programs). The 
entire set of protein spheres is partitioned into ~30 to 50 
overlapping cubes of 10 to 14 A sides. The 1000 poses are 
generated for each of these 30-50 regions and the results 
compared to select the most promising two or three putative 
binding regions. This bind site scanning procedure is used for 
agonists and antagonists separately with the hypothesis that 
an agonist might prefer a site different than an antagonist. 
The putative binding regions identified in the above scan 
ning procedure were docked with Roscovitine, and com 
pounds 7 and 9 separately, using Goddard’s DarwinDock/ 
GenDock methodology 20 to predict the binding region and 
pose preferred by these molecules. The top scoring binding 
poses were compared in terms of their pharmacophore and 
their relative binding energies. 
Preparation of AB Oligomers 
1.0 mg of AB1-42 peptide was dissolved in 120 uL of 
hexafluoroisopropanol for 60 min at room temperature, and 
placed back on ice for 5-10 min. Hexafluoroisopropanol was 
evaporated overnight in the hood at room temperature. The 
sample was dissolved by 100% DMSO by adding 20 uL of 
fresh anhydrous DMSO (Sigma Hybri-Max) to 0.45 mg of the 
peptide, and diluted to 5 mM peptide stock into medium. 
Diluted peptide was incubated at 4°C. for 24 h, and then 
centrifuged at 14,000 g for 10 min in the cold. Before treating 
slice culture with A? oligomers, the oligomers were incu 
bated at room temperature for 20 h. 
Preparation of Hippocampal Slice Cultures 
Hippocampal slice cultures were prepared from 7-10 day 
old mouse pups. Slices were cut at 400 um on a Mcllwain 
tissue chopper, transferred to Millicell (Millipore Corp., Bed 
ford, Mass.) membrane inserts (0.4 um), and placed in 6-well 
culture plated. The upper surfaces of the slices were exposed 
to a humidified 37° C. atmosphere containing 5% CO. Slice 














balanced salt solution, 20% heat-inactivated horse serum, 
enriched with glucose to a concentration of 5.6 mM. The 
medium was changed every other day. Slices were examined 
periodically for viability, and any dark or abnormal slices 
were discarded. 
Experimental Treatment of AB Oligomers to Organotypic 
Hippocampal Slice Culture 
The effects of AB oligomers were tested in the slices which 
had been maintained for 15-20 days in vitro. All reagents 
were added to serum free medium (no horse serum). Af 
oligomers were added to cultures in serum free medium. 
Vehicles were treated the same way except with no peptide. 
The slices were pretreated with compounds 6, 7, 8, 9 or cell 
cycle inhibitor Flavopiridol or Roscovitine (1 uM) for 1 h 
before AB oligomers treatment. 
Assessment of Neuronal Cell Death by PI Staining 
To analyze the degree of hippocampal neuronal cell death, 
hippocampal slices were stained by adding PI into slice cul 
ture medium at a concentration of 5ug/mL. At indicated times 
after AB oligomers treatment, the degree of hippocampal 
neuronal death was evaluated by microscopic observation of 
PI uptake as described previously. 23 Images were acquired 
through an AxioCam camera on an Axiovert 200M micro 
scope (Zeiss, Thornwood, N.Y.). The intensity of the fluores 
cence was quantitatively analyzed using Scion Image. The 
images were expressed as an arbitrary unit of PI uptake. 
Statistical Analysis 
Data were expressed as the means-S.E. of the values from 
the number of experiments indicated in the corresponding 
figures. Differences between groups were examined for sta 
tistical significance using one-way analysis of variance with 
an unpaired Students t-test. A p value less than 0.05 is denoted 
to have statistical significance. 
Synthesis of Compounds 
2-Chloro-6-benzylaminopurine (4) 
To a suspension of 2,6-dichloropurine (110 mg 0.52 
mmol) in n-butanol (3 mL), benzylamine (57 mg, 0.52 mmol) 
and triethylamine (72 mg 0.79 mmol) was added. The mix 
ture was stirred and heated at 60° C. for 15 min. The resulting 
precipitate was filtered, washed with water (20 mL) and 
methanol (10 mL), and air-dried overnight. Compound 4 (130 
mg, 95%) was obtained as an off-white solid: mp 262° C.; 
EI/MS (m/z (relative%)): 259 (19, M), 260 (14), 261 (17%), 
106 (100), 91 (77); H NMR (400 MHz, DMSO) & 8.15 (s, 
1H), 7.25-7.34 (m, 5H), 4.66 (d. J=6 Hz, 2H); 'CNMR (100 
MHz, DMSO) & 155.0 (s) 153.1 (s), 150.7 (s), 140.2 (d. 
'J, 200Hz), 139.6(s), 128.5 (d, 'J, -158 Hz, 127.5 (d. 
'J -157 Hz), 127.0 (d. J. -158 Hz) 118.1 (s), 43.4 (t, 
'J =139 Hz). 
2-Chloro-6-benzylamino-9-(2-propynyl)purine (5) 
A solution of 2-chloro-6-benzylaminopurine (1.1 g, 3.8 
mmol), in DMSO (5 mL) was cooled to 0°C., potassium 
carbonate (0.79 g, 5.7 mmol) and propargyl bromide (0.45 g, 
3.8 mmol) was added to the contents, and stirred for 1 h at 0° 
C. Water (20 mL) was then added to the reaction mixture, and 
the resulting yellow precipitate was filtered and washed with 
excess water (50 mL). Compound 5 (1.1 g, 80%) was 
obtained as an off-white solid upon Successive recrystalliza 
tion from dichloromethane and ethyl acetate: mp 180° C.; 
EI/MS (m/z (relative%)): 297 (63, M), 298 (15), 299 (23), 
258 (46), 91 (100); H NMR (400 MHz, DMSO) & 8.23 (s, 
1H), 7.21-7.38 (m, 5H), 5.03 (bs, 2H), 4.62 (d. J=6 Hz, 2H), 
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3.51 (s, 1H). ''C NMR (100 MHz, DMSO) & 155.6 (s), 
154.0 (s), 150.3 (s), 140.7 (d, 'J, 214 Hz) 139.9 (s), 128.9 
(d, J =159 Hz), 127.9 (d. J. -157 Hz), 126.8 (d. 
'J = 158 Hz), 118.1 (s), 78.5 (t, J =9 Hz) 76.7 (dt, 
'J 252 Hz, J. 4 Hz), 43.8 (t, J =126 Hz), 33.3 
(t, J =139 Hz). 
Procedure A: Synthesis of 2-Chloro-6-benzylamino 
9-(1-benzyl-1H-1,2,3-triazol-4-yl-methyl)purine (6) 
Benzyl bromide (110 mg, 0.58 mmol) was added dropwise 
to a solution of sodium azide (42 mg, 0.64 mmol) in DMSO 
(5 mL, and stirred at room temperature for 15 min. Compound 
5 (173 mg, 0.58 mmol), triethylamine (6 mg, 0.06 mmol) and 
CuBr (8 mg, 0.6 mmol) were added to the contents in that 
order, and the reaction mixture was stirred at room tempera 
ture for 30 min. The reaction mixture was poured into ice-cold 
water (20 mL), and the resulting off-white precipitate was 
filtered and washed with dilute NHOH (20 mL) and water 
(50 mL) to give the compound 6 (200 mg 80%) essentially 
pure by NMR: mp 235° C. EI/MS (m/z (relative%)): 430 (32, 
M"),431 (11),432 (13), 258 (54), (100); H NMR (400 MHz, 
DMSO) & 8.23 (s, 1H), 8.15 (s, 1H), 7.40-7.17 (m, 10H), 5.56 
(s. 2H), 5.40 (s. 2H), 4.62 (d. J=6 Hz, 2H); 'C NMR (100 
MHz, DMSO) & 155.6 (s), 153.9 (s), 150.3 (s), 143.1 (d. 
'J = 199 Hz), 141.9 (s), 139.9 (s), 136.51 (s), 129.4 (d. 
'J -160 Hz), 128.9 (d. J. -159 Hz), 128.8 (d. 
'J = 159 Hz), 128.5 (d, 'J, -158 Hz), 127.9 (overlap 
ping doublets), 127.4 (overlapping doublets), 124.4 (d. 
'J -200 Hz) 118.6 (s), 53.4 (t, J 145 Hz), 43.7 ((t, 
'J', -135 Hz), 38.9 (t, J =139 Hz). 
2-Chloro-6-benzylamino-9-1-(2-fluorobenzyl)-1H 
1,2,3-triazol-4-yl-methylpurine (7) 
Compound 7 was obtained as an off white solid (85%), 
using procedure A: mp 240° C.; EI/MS (m/z (relative %)): 
448 (44, M), 449 (14), 450 (17), 258 (83), 109 (100), 91 (67); H NMR (400 MHz, DMSO) & 8.23 (s, 1H), 8.17 (s, 
1H), 743-7.10 (m,9H), 5.60 (s.2H), 5.38 (s.2H), 4.60 (d. J=6 
Hz, 2H); 'F NMR (376MHz, CDC1)-117.37 (dd, J=14 Hz, 
8 Hz); 'C NMR (100 MHz, DMSO) & 160.7 (d, J =248 
Hz), 155.6 (s), 153.8 (s), 150.3 (s), 143.1 (d, J = 199Hz), 
142.0 (s), 139.9 (s), 131.4 (d, J =165 Hz) 131.3 (dd. 
'J -160 Hz, J-4 Hz), 128.9 (d. J. =156 Hz) 127.9 (d. J. -150 Hz), 127.4 (d, 'J, -160 Hz), 125.5 (d. 
'J -150 Hz), 124.5 (d. J. 200 Hz), 123.3 (d. 
'J -26 Hz), 118.6 (s), 116.2 (dd, J-170 Hz, J. 21 
Hz) 47.6 (t, J =130), 43.8 (t, =133 Hz), 38.9 (t, 
J. 143 Hz). 
2-Chloro-6-benzylamino-9-1-(2,6-difluorobenzyl)- 
1H-1,2,3-triazol-4-yl-methylpurine (8) 
Compound 8 was obtained as an off white solid (84%), 
using the procedure A: mp 239°C.; EI/MS (m/z (relative%)): 
466 (52, M), 467 (19), 468 (22), 258 (77), 127 (100), 91 (73); H NMR (400 MHz, DMSO) & 8.20 (s), 8.16 (s), 7.05 
7.47 (m, 8H), 5.60 (s. 2H), 5.37 (s. 2H), 4.61 (d. J. 5.5 
Hz, 2H), F NMR (376 MHz, CDC1) 8-114.10: CNMR (100 MHz, DMSO) & 1614 (dd, J =248 Hz, J =7 
Hz), 155.5 (s), 153.8 (s), 150.3 (s), 143.01 (s), 142.03 (d. 
'J = 199 Hz), 139.9 (s), 132.4 (dt, J =166 Hz, 
J. -10 Hz), 128.9 (dd, J =159 Hz, J. -6 Hz), 













‘J. -19 Hz, J. -6 Hz), 111.8 (t, J -19 Hz) 43.7 (t, 




Compound 9 was obtained as an off white solid (89%), 
using the procedure A: mp 225°C.; EI/MS (m/z (relative%)): 
520 (24%, M), 521 (6), 522 (9%), 258 (73), 181 (69), 106 (64), 91 (100); H NMR (400 MHz, DMSO) & 8.22 (s, 1H), 
8.23 (s, 1H), 7.32-7.19 (m, 5H), 5.73 (s. 2H), 5.39 (s. 2H), 
4.61 (d. J. =5.5, 2 H); 'F NMR (376 MHz, CDC1) & 
-141.70 (dd, 'J, -23.2, J –7.2 Hz, ortho-fluorines), 
-152.7 (t, J =22 Hz, para-fluorine), —161.43 (dt, 
'J 22.9, J =7.4 Hz, meta-fluorines); 'C NMR (100 
MHz, DMSO) & 155.5 (s), 153.8 (s), 150.3 (s), 145.6 (dim, 
'J -254 Hz), 143.14 (s), 142.01 (d. J. -199Hz), 141.6 (dim, 'J, -259 Hz), 137.7 (d, 'J, 249 Hz), 139.9 (s), 
128.9 (dd, J =159 Hz, J. -6 Hz), 127.9 (dim, 
'J -154 Hz), 127.5 (d, 'J, -164 Hz), 124.8 (d. 
'J =197 Hz.), 118.8 (s), 109.8 (t, J -18 Hz), 43.8 (t, 
'J =139 Hz.), 41.1 (t, J =130 Hz), 38.8 (t, 
'Jc. 142 Hz). 
Results 
Synthesis 
Referring to scheme 1, described previously, the triazole, 6, 
and its fluorinated derivatives, compounds 7-9, were prepared 
by the Sharpless-Huisgen’s Cu(I) catalyzed 1,3-dipolar 
cycloaddition reactions of the corresponding alkyne and 
azide Substrates. As expected, the products show high 1,4- 
regioselectivity in these cycloadditions. 
Reaction of the commercially available 2,6-dichloropurine 
(3) with benzylamine gave 2-chloro-6-benzylaminopurine 
(4) using a reported procedure. Under our conditions, the 
reaction was complete in 15 min at 60° C. instead of the 
reported time of 3 hat 110°C. Propargylation of compound 4 
using propargyl bromide in DMSO under mild conditions 
gave 2-chloro-6-benzylamino-9-(2-propynyl) purine (5) 
regioselectively in high yield. The Cu(I) catalyzed azide 
alkyne click reaction (the Sharpless-Huisgen 1,3-dipolar 
cycloaddition) of the alkyne 5 with fluorinated benzyl azides, 
prepared in situ from their corresponding benzyl bromides, 
gave exclusively 1,4-disubstituted triazoles, 7-9. The iso 
meric homogeneity of the product triazoles was readily veri 
fied through their 'F NMR spectra. The pentafluorophenyl 
methyl-triazole, 9, showed relatively shielded 8F 
absorptions as compared to the o-fluorophenylmethyl- and 
the 2,6-difluorophenylmethyl-triazoles, 7 and 8 respectively, 
in accordance with similar observations for the monofluoro-, 
difluoro-, and pentafluorotoluenes. 
A? has been known to overactivate CDK5 which results in 
the tau-hyperphosphorylation, and cell cycle re-entry, leading 
to neuronal apoptosis. Thus, we used AB oligomers as the 
trigger of neurotoxicity in vitro for convenient assay of the 
neuroprotective effects of the kinase inhibitors. 
Mouse hippocampal slice cultures were treated with Af 
oligomers in the presence of PI as the staining agent. The 
degree of hippocampal neuronal death was monitored by 
fluorescence microscopic observation of the PI uptake. The 
intensities of the fluorescence were conveniently analyzed 
using Scion images. The intensity of the PI fluorescence 
reflects the relative number of the dead cells, since PI cannot 
permeate the live cell membranes. As shown in FIGS. 1-2, 
there is visible difference in the control (in the absence of AB 
oligomers) and the AB oligomers-treated cell cultures. Typi 
cally 48 h is required for the expression of the AB toxicity. 
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These experiments were repeated using the established cell 
cycle inhibitors, Roscovitine, Flavopiridol, and the triazoles, 
6, 7, 8, and 9. 
As can be seen in FIGS. 3-4, after 48 h of incubation time, 
Roscovitine, Flavopiridol and the o-fluorophenylmethyl-tria 
Zole, compound 7, have neuronal cell Survival rates compa 
rable to those of the control experiments, i.e., those corre 
sponding to the cultures in the absence of the AB oligomers. 
Interestingly, the pentafluorophenylmethyl-triazole (9) has 
virtually no neuroprotective effect, and the 2,6-difluorophe 
nylmethyl-triazole (8) and the nonfluorinated-analogue (6) 
have only marginal effects. Thus the degree of fluorination 
has a dramatic effect on the neuroprotective effects of these 
compounds, implying that these compounds may serve as 
substrates for CDK5/p25 complex which is responsible for 
the cell cycle re-entry, eventually leading neuronal cell death. 
The neurotoxicity of AB peptide may arise primarily due to 
its overactivation of CDK5/p25 complex followed by cell 
cycle re-entry. Thus, selective enzyme inhibitors for CDK5/ 
10 
15 
p25 are the ideal target for designing state of the art neuro- 20 
protective agents. Goddard’s state of the art molecular dock 
ing methods, Darwin Dock/GenDock, are ideally suited in the 
design of these selective inhibitors. We have shown the valid 
ity of these calculations for CDK5/p25 by reproducing the 
Roscovitine/CDK5-p25 cocrystal structure from protein data 
bank (PDB; 1UNL). We have located three potential binding 
regions (A, B, and C: FIGS. 5-6) in CDK5/p25 and showed 
that all high scoring poses preferred Region A which is con 
sistent with the binding site observed in the co-crystal, 1UNL. 
In addition, the binding pose is within 0.17 A (heavy atom 
RMSD) of the pose observed in the co-crystal structure 
(1UNL). The predicted structure superimposed on the experi 
mental co-crystal structure (1UNL) is shown in FIG. 4. 
Docking of Compounds 7 and 9 to the three potential 
ligand binding regions predicts that these inhibitors also pre 
fer region A. The closeup view of the binding site for com 
pound 7 is shown in FIG. 7. The later site overlaps the Ros 
covitine site but the molecule has a different pose and 
interacts strongly with a different set of CDK5 residues 
except for Gln130. It shows three strong H-bonding interac 
tions with Asn144, Lys89, backbone carbonyl of Ile10, and 
relatively weaker interaction with Gln130. 
Compound 9 shows the same binding pose as Compound 7. 
as expected from the structural similarities. The relative bind 
ing energies for Roscovitine, and compounds 7 and 9 are 
-48.1 kcal/mol, 44.8 kcal/mol, and -33.3 kcal/mol, respec 
tively, which correlates well with the PI assay. The similar 
binding energies for Roscovitine and compound 7 are in 
accordance with their comparable neuroprotective effects 
(FIG. 2), whereas the much lower binding energy for the 
compound 9 is consistent with its ineffectiveness in enzyme 
binding observed in our experiments (FIG. 2). The difference 
in binding energies for compounds 7 and 9 comes mainly 
from the larger desolvation penalty needed to bury the pen 
tafluorophenyl group of Compound 9 as compared to the 
o-fluorophenyl group of compound 7. This desolvation pen 
alty difference, calculated using an implicit Solvation model 
(Poisson-Boltzmann), is about 9 kcal/mol and accounts for 
most of the reduction in binding energy of compound 9. 
In summary, we have found that our o-fluorophenylmethyl 
derived triazole, 7, effectively suppressed AB-induced neuro 
toxicity in hippocampal slice cultures, while the pentafluoro 
aryl derived triazole 9 has virtually no neuroprotective effect 
Importantly, the neuroprotective effect of compound 7 is 
comparable to Flavopiridol and Roscovitine, state of the art 
pharmaceuticals. These results suggest our newly synthe 











neurological disorders. Indeed, Darwin Dock/GenDock 
docking calculations show that the Roscovitine and the tria 
Zoles 7 and 9 all bind at the same active site region of the 
CDK5/p25 complex, with relative binding affinities of -48.1 
kcal/mol, -44.8 kcal/mol, and -33.3 kcal/mol, respectively. 
The comparable neuroprotective effects of Roscovitine and 
compound 7 are thus reflected in their similar binding affini 
ties, whereas the unfavorably low binding affinity for com 
pound 7 makes it practically inefficient neuroprotector. These 
docking simulations also support the involvement of the 
CDK5/p-25 complex in the cell cycle re-entry, a leading cause 
of the neuronal degeneration. 
From the above description of the invention, those skilled 
in the art will perceive improvements, changes and modifica 
tions. Such improvements, changes, and modifications are 
within the skill of the art and are intended to be covered by the 
appended claims. All patents and publications identified 
herein are incorporated by reference in their entirety. 
Having described the invention, the following is claimed: 
1. A compound of formula I 
(I) 
N 
R-N N e / N )---, 
or a pharmaceutically acceptable salt thereof, 
where R is a hydrophobic, substituted or unsubstituted, 
aryl, cyclic, or heterocyclic group; 
where R and R independently represent substituents 
Selected from the group consisting of hydrogen, halo 
gen, C1-C4 alkyl, C2-C2a alkenyl, C2-C2a alkynyl, 
Cs-Co aryl, C-C2a alkaryl, C-C2a aralkyl, silyl, 
hydroxyl, Sulfhydryl, C-C alkoxy, C-C alkeny 
loxy, C-C alkynyloxy, Cs-Co aryloxy, acyl, C-C 
alkylcarbonyl (—CO-alkyl). Co-Co arylcarbonyl 
(—CO-aryl)), acyloxy (—O-acyl), C-C alkoxycarbo 
nyl (-(CO)—O-alkyl). Co-Co aryloxycarbonyl 
(—(CO)—O-aryl), C-C alkylcarbonato (-O- 
(CO)—O-alkyl). Co-Co arylcarbonato ( O—(CO)— 
O-aryl), carboxy ( -COOH), carboxylato (-COO), 
carbamoyl (—(CO)—NH), mono-(C-C alkyl)-sub 
stituted carbamoyl (—(CO)—NH(CC alkyl)), di 
(C-C alkyl)-substituted carbamoyl (—(CO) N(C. 
C alkyl)), mono-Substituted arylcarbamoyl 
(—(CO). NH-aryl), thiocarbamoyl (—(CS) NH), 
carbamido ( NH (CO) NH), cyano( CN), iso 
cyano (—NC), cyanato (-O-CN), isocyanato 
(O—NC), isothiocyanato ( S. NC), azido ( N=N* 
—N), formyl (—(CO)—H), thioformyl ( (CS)—H), 
amino ( NH), mono- and di-(C-C alkyl)-substi 
tuted amino, mono- and di-(Cs-Co aryl)-substituted 
amino, C-C alkylamido (—NH-(CO)-alkyl). 
Co-Co arylamido (—NH-(CO)-aryl), imino, alky 
limino, arylimino, nitro ( NO), nitroso ( NO), Sul 
fonic acid ( SO, OH), sulfonato ( SO. O.), 
C-C alkylsulfanyl ( S-alkyl), arylsulfanyl, C-C 
alkylsulfinyl (—(SO)-alkyl), Cs-Co arylsulfinyl 
(—(SO)-aryl), C-C alkylsulfonyl (-SO-alkyl). 
Cs-Co arylsulfonyl ( -SO-aryl), phosphono ( -P(O) 
(OH)2), phosphonato (-P(O)(O—)), phosphinato 
(—P(O)(O)), phospho (—PO), and phosphino 
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(—PH), and where each RandR, being independently 
unsubstituted or substituted where appropriate by one or 
more —OH, halogen, amino or alkyl groups. 
2. The compound of claim 1, where R1 is a fluorinated aryl, 
cyclic, or heterocyclic group. 
3. The compound of claim 1, where R and Rs are each 
independently a hydrogen, a halogen, C1-C4 alkyl, C2-C24 
alkenyl, C-C alkynyl, C-Co aryl, C-C alkaryl, C-C, 
aralkyl, or an R. NH , R. NH-NH NH R' 
NH or R. NH R NH radical, in which Ra repre 
sents a straight- or branched-chain, Saturated or unsaturated 
alkyl radical, an aryl or cycloalkyl radical or a heterocyclic 
ring and R' represents a straight- or branched-chain, Saturated 
or unsaturated alkylene group or an arylene or cycloalkylene 
group, R4 and R' each containing 1 to 8 carbon atoms, and 
where each R and R being independently unsubstituted or 
substituted, where appropriate, by one or more —OH, halo 
gen, amino or alkyl groups. 
4. The compound of claim 1 having the formula (II): 
(II) 
N N-4, 
N ( ) - 
'-ty--- 
or a pharmaceutically acceptable salt thereof, 
where X is a halogen; 
where n is an integer from 0-5: 
where n is an integer from 1-3: 
where Y is substituted or unsubstituted C-C alkyl, 
C-C alkenyl, C-C alkynyl, C-Co aryl, C-C, 
alkaryl, C-C2a aralky; and 
where R is a hydrogen, a halogen, C-C alkyl, C-C, 
alkenyl, C2-C alkynyl, Cs-Co aryl, C-C alkaryl, 
C-C aralkyl, or an R. NH-, R. NH-NH-. 
NH R NH or R. NH R NH- radical, in 
which R represents a straight- or branched-chain, Satu 
rated or unsaturated alkyl radical, an aryl or cycloalkyl 
radical or a heterocyclic ring and R' represents a straight 
or branched-chain, Saturated or unsaturated alkylene 
group or an arylene or cycloalkylene group, R and R' 
each containing 1 to 8 carbon atoms, and where R is 
unsubstituted or Substituted, where appropriate, by one 
or more —OH, halogen, amino or alkyl groups. In one 











5. The compound of claim 1, having the formula (III) 
(III) 
Or e | \, x- )-- S-C R 
or a pharmaceutically acceptable salt thereof, 
where n is an integer from 0-5; and ortho-, meta- and 
para-isomers, 
where R2 is a hydrogen, a halogen, C1-C4 alkyl, C2-C24 
alkenyl, C-C alkynyl, C-Co aryl, C-C alkaryl, 
C-C aralkyl, or an R. NH , R. NH-NH-, 
NH R NH or R. NH R NH- radical, in 
which R represents a straight- or branched-chain, Satu 
rated or unsaturated alkyl radical, an aryl or cycloalkyl 
radical or a heterocyclic ring and R' represents a straight 
or branched-chain, Saturated or unsaturated alkylene 
group or an arylene or cycloalkylene group, R and R' 
each containing 1 to 8 carbon atoms, and where R is 
unsubstituted or Substituted, where appropriate, by one 
or more —OH, halogen, amino or alkyl groups. 
6. The compound of claim 1, where R2 is C1, F, an alkyl or 
substituted alkyl. 
7. A pharmaceutical composition comprising a compound 
according to claim 1, admixed with a pharmaceutically 
acceptable diluent, excipient, carrier or mixtures thereof. 
8. A method for promoting neuron Survival in the presence 
of amyloid B, the method comprising: 
administering to a neuron in the presence of amyloid B a 
therapeutically effective amount of a compound accord 
ing to claim 1. 
9. A method for treating a neurological disorder wherein 
the neurological disorder is Alzheimer's disease in a Subject, 
the method comprising: 
administering to the subject a therapeutically effective 
amount of a compound according claim 1, and a phar 
maceutical carrier. 
10. The method of claim 9, the neurological disorder being 
mediated by amyloid B. 
11. The method of claim 9, the compound being adminis 
tered at an amount effective to promote neuronal Survival. 
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